Gender identity: Current concepts and gender-affirming hormone therapy | Endocrinología, Diabetes y Nutrición (English ed.)

array:24 ["pii" => "S2530018022001652" "issn" => "25300180" "doi" => "10.1016/j.endien.2022.11.007" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1305" "copyright" => "SEEN and SED" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:27-37" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2530016422001185" "issn" => "25300164" "doi" => "10.1016/j.endinu.2022.02.007" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1305" "copyright" => "SEEN y SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:27-37" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "REVISIÓN" "titulo" => "Identidad de género: Conceptos actuales y tratamiento hormonal de afirmación de género" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "27" "paginaFinal" => "37" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Gender identity: Current concepts and gender-affirming hormone therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1300 "Ancho" => 2508 "Tamanyo" => 283809 ] ] "descripcion" => array:1 [ "es" => "Resumen de los conceptos más relevantes relacionados con el género y la sexualidad." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gilberto Pérez López" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Gilberto" "apellidos" => "Pérez López" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2530018022001652" "doi" => "10.1016/j.endien.2022.11.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001652?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001185?idApp=UINPBA00004N" "url" => "/25300164/00000070000000S1/v3_202306211155/S2530016422001185/v3_202306211155/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2530018022001664" "issn" => "25300180" "doi" => "10.1016/j.endien.2022.11.008" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1312" "copyright" => "SEEN and SED" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:38-50" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Consensus document" "titulo" => "Executive summary of the SEEN (Sociedad Española de Endocrinología y Nutrición[Spanish Society of Endocrinology and Nutrition])-SEGO (Sociedad Española deGinecología y Obstetricia [Spanish Society of Gynaecology and Obstetrics]) consensusdocument on the management of thyroid dysfunction during pregnancy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "38" "paginaFinal" => "50" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Resumen ejecutivo del documento de consenso SEEN-SEGO sobre el manejo de la disfunción tiroidea durante el embarazo" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1580 "Ancho" => 2175 "Tamanyo" => 228204 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Differential diagnosis of thyroid hyperfunction in the first trimester." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Inés Velasco, Lluís Vila, Maria Goya, Amelia Oleaga, Maria de la Calle, Fco. Javier Santamaria" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Inés" "apellidos" => "Velasco" ] 1 => array:2 [ "nombre" => "Lluís" "apellidos" => "Vila" ] 2 => array:2 [ "nombre" => "Maria" "apellidos" => "Goya" ] 3 => array:2 [ "nombre" => "Amelia" "apellidos" => "Oleaga" ] 4 => array:2 [ "nombre" => "Maria" "apellidos" => "de la Calle" ] 5 => array:2 [ "nombre" => "Fco. Javier" "apellidos" => "Santamaria" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2530016422001410" "doi" => "10.1016/j.endinu.2022.03.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001410?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001664?idApp=UINPBA00004N" "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001664/v2_202304211110/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2530018022001640" "issn" => "25300180" "doi" => "10.1016/j.endien.2022.11.006" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1290" "copyright" => "SEEN and SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:7-26" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Consensus document" "titulo" => "Consensus document on the management of hyponatraemia of the Acqua Group of the Spanish Society of Endocrinology and Nutrition" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "7" "paginaFinal" => "26" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Documento de consenso sobre el manejo de la hiponatremia del Grupo Acqua de la Sociedad Española de Endocrinología y Nutrición" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1613 "Ancho" => 2343 "Tamanyo" => 351727 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0025" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Adjustment protocol for outpatient tolvaptan treatment in patients with syndrome of inappropriate ADH secretion (SIADH).<a class="elsevierStyleCrossRef" href="#bib0325">65</a> NaS: serum sodium; GS: glucose serum; TV: tolvaptan." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "David E. Barajas Galindo, Jorge Gabriel Ruiz-Sánchez, Alberto Fernández Martínez, Isabelle Runkle de la Vega, Juan Carlos Ferrer García, Guillermo Ropero-Luis, Ana Ortolá Buigues, Joaquín Serrano Gotarredona, Emilia Gómez Hoyos" "autores" => array:9 [ 0 => array:2 [ "nombre" => "David E." "apellidos" => "Barajas Galindo" ] 1 => array:2 [ "nombre" => "Jorge Gabriel" "apellidos" => "Ruiz-Sánchez" ] 2 => array:2 [ "nombre" => "Alberto" "apellidos" => "Fernández Martínez" ] 3 => array:2 [ "nombre" => "Isabelle Runkle" "apellidos" => "de la Vega" ] 4 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Ferrer García" ] 5 => array:2 [ "nombre" => "Guillermo" "apellidos" => "Ropero-Luis" ] 6 => array:2 [ "nombre" => "Ana" "apellidos" => "Ortolá Buigues" ] 7 => array:2 [ "nombre" => "Joaquín" "apellidos" => "Serrano Gotarredona" ] 8 => array:2 [ "nombre" => "Emilia" "apellidos" => "Gómez Hoyos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2530016422001045" "doi" => "10.1016/j.endinu.2022.01.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001045?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001640?idApp=UINPBA00004N" "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001640/v2_202304211110/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Gender identity: Current concepts and gender-affirming hormone therapy" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "27" "paginaFinal" => "37" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Gilberto Pérez López" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Gilberto" "apellidos" => "Pérez López" "email" => array:1 [ 0 => "gperezl@salud.madrid.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Co-director del Curso Universitario Experto en Medicina Transgénero de la SEEN, Universidad de Barcelona, Editorial Panamericana, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Identidad de género: Conceptos actuales y tratamiento hormonal de afirmación de género" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1309 "Ancho" => 2478 "Tamanyo" => 292189 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0030" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Summary of the most important concepts related to gender and sexuality." ] ] ] "textoCompleto" => "IntroductionAs trans people have made advances in their legitimate rights, they have gained greater relevance in the health field. Healthcare for trans people requires a holistic approach in which the endocrinologist plays a crucial role in coordinating and covering all the needs of these people.More generally, research on the health of transgender people continues to tend to represent this group as somewhat homogeneous and lacking in diversity in areas such as ethnicity, gender identity and sexuality, when in clinical practice we find complexity and heterogeneity.Transgender medicine<a class="elsevierStyleCrossRef" href="#bib0005">1</a> is a new field of medical knowledge concerned with the multidisciplinary care of trans people, from a depathologising perspective,<a class="elsevierStyleCrossRef" href="#bib0010">2</a> in order to achieve the best standards of health. This increased interest in transgender medicine is due in large part to heightened awareness of the medical needs of transgender people in the healthcare setting.Advances in transgender medicine, the complexity of diverse trans identities and the impact of hormone therapy on the quality of life and risk of middle- and long-term complications in trans people force us to examine in more detail an individualised biopsychosocial approach that requires specific training in this area of knowledge, as well as updating on the concepts, terminology and drug treatments used.Relevant concepts in transgender medicineEach individual is a composite of gender and sexuality (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Both concepts have a biological component and a social construct. But it is these two basic concepts that usually cause enormous confusion, so it is necessary to establish the differences between them.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Gender<a class="elsevierStyleCrossRef" href="#bib0015">3</a> refers to the social attributes and opportunities associated with being a man or a woman, and the relationships between men and women, and boys and girls. These attributes, opportunities and relationships are established and learned in society, are context- and time-specific, and may change — they are dynamic (for example, more and more men do housework). Gender determines what is expected, permitted and valued in a man or woman in a given context.In more academic terms, we can identify three components of gender<a class="elsevierStyleCrossRef" href="#bib0010">2</a>:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">□Gender identity</li><li class="elsevierStyleListItem" id="lsti0010">□Gender expression</li><li class="elsevierStyleListItem" id="lsti0015">□Biological sex</li></ul>Gender identity<a class="elsevierStyleCrossRefs" href="#bib0015">3,4</a> refers to the inner individual experience of gender, as each person deeply feels it, which may or may not correspond to the sex assigned at birth, including the personal experience of the body. This experience of gender is intimate, diverse and complex, and answers the question "Who am I?".Gender identity was previously considered as something dichotomous or binary (male or female), but nowadays it is understood as a spectrum where being a man or a woman are the extremes and in between there are different identities. This is called non-binary gender: a spectrum of gender identities and expressions stemming from a rejection of the binary assumption of gender as a strictly exclusive choice between man/male/masculine or woman/female/feminine, based upon the sex assigned at birth.<a class="elsevierStyleCrossRefs" href="#bib0025">5,6</a>The terms "cisgender" and "transgender" are used to describe the congruence or incongruence of one's felt gender identity with one's sex assigned at birth. Cisgender (the prefix cis is commonly used as a short form) describes a person whose gender identity is consistent with their sex assigned at birth. Transgender (the prefix trans is commonly used as a short form) is an umbrella term used to describe a person whose gender identity does not correspond with their sex assigned at birth.Gender expression refers to a person's outward presentation of gender, and includes personal style, dress, hair, make-up, jewellery, vocal inflection and body language. It is typically categorised as feminine, masculine or androgynous. All people express a gender. It may be consistent or inconsistent with a person's gender identity.Strictly speaking, the term sex<a class="elsevierStyleCrossRef" href="#bib0015">3</a> refers to: the biological differences between men and women; their physiological characteristics; the sum of the biological characteristics that define the spectrum of humans as women or men; and the biological construct that refers to the genetic, hormonal, anatomical and physiological characteristics based upon which a person is classified as male or female at birth.Sexuality is a central aspect of human beings that is present throughout their lives. It encompasses gender roles, sexual orientation, eroticism, pleasure, intimacy and reproduction. It is felt and expressed through thoughts, fantasies, desires, beliefs, attitudes, values, behaviours, practices, roles and relationships.While sexuality<a class="elsevierStyleCrossRefs" href="#bib0015">3,4</a> may include all of these dimensions, not all of them are always experienced or expressed. Sexuality is influenced by the interaction of biological, psychological, social, economic, political, cultural, ethical, legal, historical, religious and spiritual factors. Sexuality includes one of the concepts that creates the most confusion in healthcare and social settings: sexual orientation.An individual's sexual orientation<a class="elsevierStyleCrossRefs" href="#bib0020">4,5</a> is independent of their biological sex or gender identity. It has been defined as each person's ability to feel a deep emotional, affective and sexual attraction for people of a gender other than their own, or of the same gender, or of more than one gender, as well as the ability to maintain intimate and sexual relationships with these people. The terms heterosexuality, homosexuality and bisexuality come under the heading of sexual orientation.Transgender medicine terminologyConcepts related to gender identity have evolved at great speed in recent years. These concepts are dynamic, so constant updating is required.Given the increased demand for healthcare from trans people, it is necessary to use a uniform language that enables people with different trans identities to be treated in a dignified and non-pathologising way.According to the 2020 report "Las personas trans y su relación con el sistema sanitario"<a class="elsevierStyleCrossRef" href="#bib0035">7</a> [Trans people and their relationship with the healthcare system] from the Federación Española de Lesbianas, Gais, Trans y Bisexuales (FELGTB) [Spanish Federation of Lesbian, Gay, Trans and Bisexual People]), 48% of trans people reported having experienced discriminatory or inappropriate treatment from healthcare staff, and the majority of them reported that said professionals were not aware of current gender identity-related terminology.<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> lists the most important concepts and commonly used terminology in gender identity consultations, which are necessary for establishing adequate communication and a good doctor-user relationship.<a class="elsevierStyleCrossRefs" href="#bib0040">8–15</a><elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Gender-affirming hormone therapyEndocrinologists are called upon to coordinate the comprehensive care of trans people and, therefore, we are responsible for part of the medical transition, which includes gender-affirming hormone therapy (GAHT).<a class="elsevierStyleCrossRef" href="#bib0080">16</a> GAHT is the use of hormonal and non-hormonal medicines to achieve physical changes consistent with the patient's felt gender identity (binary or non-binary) as part of a gender-affirmative approach.Starting GAHT is an important step for trans people and requires a prior biopsychosocial assessment, which enables the endocrinologist to prescribe safe treatment agreed upon with the person who wishes to start transitioning.Most of Spain's Autonomous Communities (ACs) have laws protecting trans people that regulate and govern, among other things, the healthcare of these people. In the absence of a nationwide trans law, most ACs recognise gender self-identification (including Madrid, Andalusia and the Valencian Community), so a psychological/psychiatric report prior to GAHT is not needed (in much of the country), but psychological support is offered.On 29 June 2021, the Spanish Council of Ministers presented a draft bill for the real and effective equality of trans people and for the guarantee of the rights of LGBTI people, which is under consideration and seeks to harmonise healthcare for trans people across Spain.During a person's transition, it is necessary not only to prescribe treatment but also to support them, monitor the safety and efficacy of the treatment and guide them towards achieving the appearance with which they really identify. Informed consent (IC) must be obtained before GAHT is initiated.IC is not just a patient/user right, it is also a mechanism that gives legal protection to endocrinologists prescribing GAHT. In the case of minors or people with disabilities, the consent form must be signed by BOTH parents or legal guardians (Spanish Penal Code: articles 155 and 156).<a class="elsevierStyleCrossRef" href="#bib0085">17</a> It must be remembered that even if a parent does not have custody, they almost always retain parental authority. If one of the parents/guardians does not give their consent for the treatment, the GAHT cannot be started, since that would contravene the penal code. In this last circumstance in which the parents disagree, the final decision must be taken by a juvenile court, based on the best interests of the minor.The free, conscious desire of the trans person to start hormone therapy is not enough to initiate GAHT; they must also not have any serious clinical or psychiatric conditions that put their own health or adequate compliance with treatment at risk. In this regard, it is very important not to fall into downplaying or exaggerating the risks involved. The latter (magnifying the risks associated with hormone therapy) is sometimes a major obstacle when starting GAHT.Contraindications to this treatment can be classified according to the type of GAHT<a class="elsevierStyleCrossRefs" href="#bib0045">9,10,16</a>:Feminising GAHT:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0020">□Active oestrogen-sensitive cancer (absolute contraindication).</li><li class="elsevierStyleListItem" id="lsti0025">□Unstable ischaemic heart disease (absolute contraindication).</li><li class="elsevierStyleListItem" id="lsti0030">□Severe cerebrovascular disease (stroke).</li><li class="elsevierStyleListItem" id="lsti0035">□Thrombophilia (hereditary or acquired) and/or history of thromboembolic events.</li><li class="elsevierStyleListItem" id="lsti0040">□Prolactinoma (prolactin-producing pituitary adenoma).</li><li class="elsevierStyleListItem" id="lsti0045">□Uncontrolled psychosis.</li><li class="elsevierStyleListItem" id="lsti0050">□Poorly controlled diabetes.</li><li class="elsevierStyleListItem" id="lsti0055">□Severe kidney or liver disease.</li><li class="elsevierStyleListItem" id="lsti0060">□Severe hypertriglyceridaemia.</li><li class="elsevierStyleListItem" id="lsti0065">□Psychiatric conditions that limit the ability to provide informed consent.</li><li class="elsevierStyleListItem" id="lsti0070">□Hypersensitivity (allergy) to one of the ingredients of the oestrogen formulation or other hormone preparations.</li><li class="elsevierStyleListItem" id="lsti0075">□Those with a strong family history of breast and/or ovarian cancer should be referred for genetic counselling to undergo screening for familial cancer in order to clarify their individual risk.</li></ul>Masculinising GAHT:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0080">□Pregnancy or breastfeeding (absolute contraindication).</li><li class="elsevierStyleListItem" id="lsti0085">□Active androgen-sensitive cancer (absolute contraindication).</li><li class="elsevierStyleListItem" id="lsti0090">□Unstable ischaemic heart disease.</li><li class="elsevierStyleListItem" id="lsti0095">□Severe cerebrovascular disease (stroke).</li><li class="elsevierStyleListItem" id="lsti0100">□Thrombophilia (hereditary or acquired, such as that associated with antiphospholipid syndrome) and/or history of thromboembolic events.</li><li class="elsevierStyleListItem" id="lsti0105">□Active endometrial cancer.</li><li class="elsevierStyleListItem" id="lsti0110">□Uncontrolled psychosis.</li><li class="elsevierStyleListItem" id="lsti0115">□Poorly controlled diabetes.</li><li class="elsevierStyleListItem" id="lsti0120">□Severe kidney or liver disease.</li><li class="elsevierStyleListItem" id="lsti0125">□Severe hypertriglyceridaemia.</li><li class="elsevierStyleListItem" id="lsti0130">□Psychiatric conditions that limit the ability to provide informed consent.</li><li class="elsevierStyleListItem" id="lsti0135">□Hypersensitivity (allergy) to one of the ingredients of the testosterone formulation or other hormone preparations.</li><li class="elsevierStyleListItem" id="lsti0140">□Those patients with a strong family history of breast and/or ovarian cancer should be referred for genetic counselling to undergo screening for familial cancer in order to clarify their individual risk.</li></ul>Most of these contraindications are relative, in the sense that they require clinical stabilisation (controlling diabetes, decreasing triglycerides or waiting at least six months after a major cardiovascular event) before being able to start hormone therapy. They delay GAHT, but do not contraindicate it from the outset.As regards complementary tests before starting GAHT, generally speaking, apart from laboratory tests (complete blood count, biochemical and basic clotting tests, gonadal profile), other complementary tests (such as karyotype test, thrombophilia test and breast/pelvic ultrasound) are not routinely recommended,<a class="elsevierStyleCrossRefs" href="#bib0045">9,10</a> unless the medical history, personal or family history and/or physical examination suggest the existence of comorbidities.Ordering unjustified complementary tests is one of the factors that delay the start of hormone therapy and increase healthcare costs.General considerations<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0145">1)The goals of gender-affirming hormone therapy (GAHT) in trans people are determined by various factors, including: age, ability to consent to treatment, pre-existing health problems, risk of future development of diseases, access to care and user desire during the transition.</li><li class="elsevierStyleListItem" id="lsti0150">2)Trans people should be asked about gamete preservation before starting GAHT and given advice and guidance on realistic expectations of masculinisation/feminisation, and when such changes will begin to occur.</li><li class="elsevierStyleListItem" id="lsti0155">3)The first consultation should include identification of potential risks for GAHT: smoking, alcohol consumption and risk behaviours, family history of cancer (gynaecological, breast and prostate), cardiovascular disease, diabetes, hypertension and dyslipidaemia.</li><li class="elsevierStyleListItem" id="lsti0160">4)It is advisable to offer psychological support to manage expectations before, during and after transitioning.</li><li class="elsevierStyleListItem" id="lsti0165">5)Physical examination (of the breasts and genitals) can cause anxiety and discomfort; it must always be performed only with the explicit consent of the person and be approached in a sensitive, respectful manner.</li><li class="elsevierStyleListItem" id="lsti0170">6)Signed inform consent must always be obtained (in the case of minors under 18 years of age and people with intellectual disabilities, the consent form must also be signed by both parents and/or legal guardians).</li></ul><a class="elsevierStyleCrossRefs" href="#tbl0010">Tables 2 and 3</a> summarise the hormone preparations commonly used in masculinising and feminising GAHT,<a class="elsevierStyleCrossRefs" href="#bib0090">18–27</a> including some important comments on their safety.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia>The initiation of gender-affirming hormone therapy is as important as follow-up to ensure changes occur at a timely pace, to adjust treatment, and to monitor/identify any related adverse effects.Although the various guidelines recommend variable follow-up times, they all agree that most of the serious adverse effects associated with GAHT occur in the first year, so a check-up every three to six months is recommended. In any case, it should be clarified that most of those recommendations (which include GAHT) are based on evidence that is of low quality or has not been directly established at the present time, and the drugs are used off-label.<a class="elsevierStyleCrossRefs" href="#bib0130">26,27</a> Therefore, these are high-priority research areas.The demand for GAHT has increased in recent years, mostly driven by adolescents and young adults. Meanwhile, there is a minority of people on GAHT who may ask to detransition<a class="elsevierStyleCrossRef" href="#bib0140">28</a>: a procedure to reverse the changes made in the gender reassignment process, whether medical, social or administrative. Detransitioning may or may not be associated with identity desistance.However, it is believed that the existence of cases of detransitioning does not invalidate the need for public, specialised healthcare for these people, from which the majority clearly benefit, with psychological support being a useful tool throughout the transitioning process.GAHT in non-binary trans peopleThe few existing studies<a class="elsevierStyleCrossRef" href="#bib0105">21</a> have indicated that non-binary trans people represent 25−35% of trans people attending transgender medicine consultations. In Spain,<a class="elsevierStyleCrossRef" href="#bib0120">24</a> one in four people under the age of 30 identifies with a non-binary identity.What they want from GAHT can range from the complete loss of secondary sexual characteristics (demasculinisation or defeminisation) to the complete acquisition of the appearance of the felt gender identity.<a class="elsevierStyleCrossRef" href="#bib0125">25</a> In this regard, there may even be people who do not need GAHT to transition (agender or bigender).Being aware of the reality of this group is key to providing adequate care in transgender medicine consultations. Before indicating GAHT in this group, it is very important to know the desires and expectations of each person in depth: to individualise.ConclusionsTransgender healthcare is a rapidly growing field, with an exponential increase in published research in recent years. Research and practice in transgender medicine have not always been sensitive to trans people, since most studies have focused on a biological cause rather than on improving their health.At present, there are high-priority research topics in this field, such as the causes of excess morbidity and mortality, cardiovascular risk and cancer, the impact of GAHT on mental health, ageing, and sexual and reproductive health. Urgent updates are also needed to Spanish clinical practice guidelines<a class="elsevierStyleCrossRef" href="#bib0145">29</a> for managing gender identity, since the existing ones have become outdated and, in some respects, run contrary to the current approach to sexual and gender diversity.Advances in transgender medicine, the complexity of diverse trans identities, the impact of hormone therapy on quality of life and the risk of medium and long-term complications for trans people force us to study in more detail an individualised biopsychosocial approach. Endocrinologists have historically been at the forefront of hormone therapy, but as the demand, diversity and complexity of our users increase, we need to be able to offer a holistic view of their needs.FundingI have not received any funding for this review.Conflicts of interestThe author declares that he/she has no conflicts of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres1887358" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1634486" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1887359" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1634485" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Relevant concepts in transgender medicine" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Transgender medicine terminology" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Gender-affirming hormone therapy" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "General considerations" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "GAHT in non-binary trans people" ] 10 => array:2 [ "identificador" => "sec0035" "titulo" => "Conclusions" ] 11 => array:2 [ "identificador" => "sec0040" "titulo" => "Funding" ] 12 => array:2 [ "identificador" => "sec0045" "titulo" => "Conflicts of interest" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-01-02" "fechaAceptado" => "2022-02-06" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1634486" "palabras" => array:6 [ 0 => "Transgender" 1 => "Cisgender" 2 => "Transition" 3 => "Gender-affirming hormone therapy" 4 => "Nonbinary gender" 5 => "Transgender medicine" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1634485" "palabras" => array:6 [ 0 => "Transgénero" 1 => "Cisgénero" 2 => "Transición" 3 => "Tratamiento hormonal de afirmación de género" 4 => "Género no binario" 5 => "Medicina transgénero" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "In the past five years, healthcare organisation for trans people in Spain has changed as laws intended to protect sexual and gender diversity have been put in place. As a result, endocrinologists are not only on the front lines (understood as prescribing and following up gender-affirming hormone therapy) but also coordinating multidisciplinary healthcare for these individuals.Advances in transgender medicine, the complexity of diverse trans identities and the impact of hormone therapy on quality of life and risk of middle- and long-term complications call for in-depth examination of a personalised biopsychosocial approach to trans people that requires specific training in this field of knowledge as well as updates on the concepts, terminology and drug treatments used." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "En los últimos 5 años la organización de la atención sanitaria a las personas Trans en España ha cambiado en la medida que se han puesto en marcha leyes que tienen como objetivo la protección de la diversidad sexual y de género. Esto ha hecho que los endocrinólogos no sólo estemos en la primera línea (entendida como la prescripción y seguimiento del tratamiento hormonal de afirmación de género) sino que además coordinemos la atención sanitaria multidisciplinar de estas personas.El avance de la Medicina Transgénero, la complejidad de las diversas identidades Trans así como el impacto del tratamiento hormonal en la calidad de vida y en el riesgo de complicaciones a medio y largo plazo, nos obliga a profundizar en un abordaje bio-psico-social e individualizado de las personas Trans que requiere de una formación específica en esta área de conocimiento así como de la actualización de los conceptos, terminología y tratamientos farmacológicos utilizados." ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1309 "Ancho" => 2478 "Tamanyo" => 292189 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0030" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Summary of the most important concepts related to gender and sexuality." ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0035" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "ICD: International Classification of Diseases, published by the World Health Organization." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Concept/terms \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Definition \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Trans depathologisation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A theoretical/activist perspective that, rather than conceptualising gender diversity as a mental disorder, defends the recognition and protection of gender expression and identity as human rights. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">LGBTQI+ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">An initialism used as an umbrella term that attempts to encompass all genders and sexual minorities as well as identities outside of the cisgender and heteronormative binaries. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender dysphoria \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">According to the DSM-5, clinically significant distress from incongruence between felt gender identity and sex assigned at birth. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transsexualism \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">According to the ICD-10, it is the desire to live and be accepted as a member of the opposite sex, which is often accompanied by feelings of discomfort or disagreement with one's own anatomical sex and the desire to undergo surgery or hormone therapy to make one's own body match the preferred sex as closely as possible. Term in disuse (currently the ICD-11 is in force). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transsexuality \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">According to the ICD-10, a concept that indicates congruence between biological sex as defined by genitalia assigned at birth with conviction of being and identification with the opposite gender. Term in disuse (the ICD-11 is currently in force). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transsexual \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A person who has feelings of being born with the wrong physical sex. This term is also used to describe a person who presents physical changes due to hormone therapy and/or surgery. The use of this term is not recommended (transgender or trans are preferred). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender incongruence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">According to the ICD-11, it is the marked, persistent incongruence or lack of conformity between a person's experienced gender and assigned sex, which often leads to a desire to transition in order to live and be accepted as a person of the experienced gender. The terms gender mismatch, gender discomfort and gender nonconforming are commonly used as synonyms. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Binary gender \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">It is the idea that gender is a strict choice between man/male/masculine and woman/female/feminine, based on the sex assigned at birth. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Non-binary gender \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A spectrum of gender identities and expressions based on the rejection of the binary assumption of gender as a strictly exclusive choice between man/male/masculine and woman/female/feminine, based on the sex assigned at birth. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Misgendering \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A term used when somebody identifies a trans person with a gender other than their felt gender. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Deadname \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A term that refers to the name given at birth to a trans or non-binary person before they assumed their current gender identity (or any name with which they previously identified). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Deadnaming \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The act of calling a person by the name given to them by their parents or legal guardians at birth, and not by their felt name. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender self-identification \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A process in which a person legally and freely recognises their gender identity through an express declaration, with no need to present a medical diagnosis or meet any other requirement, such as the presence of witnesses. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psychological support \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psychotherapy is viewed as a facilitating intervention in the process of personal growth and the development of one's own psychic autonomy, not as a technique for curing or diagnosing any type of mental disorder. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender-affirming approach \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">An approach to gender identity in social and healthcare settings that respects and accepts people's gender self-identification. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transitioning \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A process by which a person outwardly manifests their felt gender identity. While unique to each individual, the ultimate goal of transitioning is to be able to be seen, known and related to according to the core experience of self. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender-affirming hormone therapy (GAHT) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The use of hormonal and non-hormonal medications to achieve physical changes consistent with the felt gender identity (binary or non-binary) based on the gender-affirmative approach. It is recommended that gender-affirming hormone therapy be used instead of cross-sex hormone therapy. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender-affirming surgery \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Surgical procedures that align physical characteristics with the felt gender. This term is now preferred over sex reassignment surgery. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Basic concepts in transgender medicine and commonly used terminology." ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0040" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "GAHT: gender-affirming hormone therapy; SL: sublingual; IM: intramuscular; SC: subcutaneous; DVT: deep vein thrombosis; AMAB: assigned male at birth.ACs: Autonomous Communities; DVT: deep vein thrombosis; CHF: congestive heart failure; PSA: prostate specific antigen." "tablatextoimagen" => array:2 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_colgroup " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Antiandrogens</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GnRH analogues</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Triptorelin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.75-mg and 7.25-mg vial \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.75mg/28 days \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Good tolerance. Commonly used in adults in the United Kingdom and the Netherlands. In Spain, it is used in a minority of cases due to its price, although it is subsidised by some ACs. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.25mg/3 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">May prolong QT interval. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progestogens</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cyproterone acetate<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.5−25mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inhibits secretion of gonadotropins and blocks androgen receptors. Assess its contraindications. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dienogest \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2−3mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progestagen with antiandrogen activity (40–60% compared to cyproterone). Preferably use in combination with oestradiol valerate (some combinations contain ethinyloestradiol) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Drospirenone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5-mg and 3-mg tablets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5−3mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progestagen with antiandrogen activity (40−60% compared to cyproterone) and aldosterone antagonist (as it is derived from spironolactone. Preferably used in combination with oestradiol valerate (some combinations contain ethinyloestradiol). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Androgen receptor antagonists</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Spironolactone<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25-mg and 100-mg tablets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100−400mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Monitor blood pressure. Inexpensive. Risk of liver toxicity. Diarrhoea and rash. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Flutamide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">250-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">250−500mg/day (1−2 doses) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Risk of liver toxicity and thromboembolic disease. Increases oestradiol (increased risk of DVT). Adjust dose of oestrogens and anticoagulants. May prolong QT interval. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bicalutamide<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25−50mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Contraindicated in interstitial lung disease. Liver toxicity. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5α-reductase inhibitors</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Finasteride \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Useful following gonadectomy. Contains lactose. Monitor PSA. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dutasteride \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.5mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Interaction with ritonavir/indinavir and calcium channel blockers. Monitor PSA. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] 1 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Feminising preparations</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Micronised oestradiol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral/sublingual \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2-mg tablets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral: 2−4mg/day in two doses. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Of choice when starting GAHT: a plasma oestrone-to-oestradiol ratio of 5:1 promotes breast bud formation. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oestradiol valerate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral/sublingual \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-mg and 2-mg tablets in combination with progestagens. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SL: 0.5−4mg/day in two doses. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The sublingual route (as an alternative to the transdermal or intramuscular/subcutaneous route) is recommended from Tanner stage 3−4 of breast development to promote glandular hyperplasia). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IM/SC<a class="elsevierStyleCrossRef" href="#tblfn0020">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ampoules in concentrations of 5, 20 and 40mg/ml \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2−4mg weekly \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100% bioavailability. Achieves suppression of testosterone secretion without requiring antiandrogens. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ethinyloestradiol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.02−0.03mg tablets combined with progestagens \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.02−0.03mg/day (20−30μg/day) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Always as a last resort: Increased risk of DVT. In regular clinical practice, it is not possible to measure plasma levels. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transdermal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Extended-release patch \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33.9μg/24h in combination with progestagens (for 7 days). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oestradiol hemihydrate (patches)<a class="elsevierStyleCrossRef" href="#tblfn0025">e</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transdermal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patches of 25, 50, 75 and 100μg/24h (for 3−4 days). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100−200 μg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low risk of DVT. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oestradiol hemihydrate (gel)<a class="elsevierStyleCrossRef" href="#tblfn0025">e</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gel at a concentration of 0.6mg/g \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3−6mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oestradiol hemihydrate (spray)<a class="elsevierStyleCrossRef" href="#tblfn0025">e</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Each spray administers 1.53mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6−9mg/day (in 2−3 doses) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Low risk of DVT. With this formulation, lower oestradiol peaks are obtained – up to 60% less (versus gel). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Micronised progesterone<a class="elsevierStyleCrossRef" href="#tblfn0030">f</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100-mg and 200-mg capsules \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100−200mg oral/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Do not confuse progesterone with medroxyprogesterone. This medicine contains peanut and/or soybean oil and therefore should not be used in people with allergies to these foods. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Given the limited evidence of its effects on the growth of mammary alveoli, its widespread use is not recommended in trans/AMAB women. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">May increase risk of thrombosis. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rectal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100mg rectally at bedtime \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:6 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Cyproterone acetate: contraindicated in severe depression, liver disease, thromboembolic disease or diabetes mellitus with microangiopathic involvement. May increase the risk of meningiomas: monitor cumulative dose." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Spironolactone: although uncommon, if the patient develops a skin rash or general malaise, treatment should be suspended and the patient should be referred to the emergency department immediately (drug rash with eosinophilia and systemic symptoms [DRESS] syndrome)." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "Bicalutamide: contraindicated if there is a history of ischaemic heart disease or chronic heart failure. Do not use in interstitial lung disease, liver disease or prolonged QT interval (as with flutamide). Interaction with ritonavir/indinavir and calcium channel blockers (verapamil and diltiazem). It should not be used as the first option, given its potential adverse effects." ] 3 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "d" "nota" => "Oestradiol valerate injection: commonly used in the US and Latin America, as well as in Eastern Europe. There are currently no formulations on the market in Spain." ] 4 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "e" "nota" => "Transdermal oestradiol: contact sensitisation occurs with all topical applications. Although extremely rare, women who develop contact sensitisation to any of the components of the patch should be warned that a serious hypersensitivity reaction could develop with continued exposure." ] 5 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "f" "nota" => "Progesterone: May be indicated in trans women (<50 years of age) who do not achieve breast development beyond Tanner stage 3 despite receiving suitable doses of oestradiol and being on hormone therapy for more than 12–18 months. If after six months there is no response, it should be suspended." ] ] ] "descripcion" => array:1 [ "en" => "Drugs used in feminising GAHT." ] ] 3 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0045" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "IM: intramuscular; SC: subcutaneous." "tablatextoimagen" => array:2 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n \t\t\t\t\ttable-head\n \t\t\t\t ; entry_with_role_colgroup " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Masculinising hormones<a class="elsevierStyleCrossRef" href="#tblfn0035">a</a></th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentation \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Testosterone cypionate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100-mg and 250-mg ampoule \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100mg every 14 days \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Short-acting preparations. Does not mimic circadian rhythm. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">250mg every 21 days \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">SC<a class="elsevierStyleCrossRef" href="#tblfn0040">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50−100mg SC weekly \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The same preparation is used intramuscularly (off label). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Testosterone undecanoate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-g ampoule \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1g/3 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">First dose of 1g IM, second dose at 6 weeks and then 1g IM every 3 months. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Testosterone (gel)<a class="elsevierStyleCrossRef" href="#tblfn0045">c</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Transdermal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50-mg/5-g sachet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 sachet per day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Risk of transfer to partner \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20mg/g (2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4−6 applications/day (40−60mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 application=0.5g of gel=10mg of testosterone \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16.2mg/g \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2−3 applications/day (40.5−60.75mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 application=1.25g of gel=20.25mg of testosterone \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] 1 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Other preparations for use in trans men</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentation \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progestagens: to stop menstruation or as contraceptives</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Norethisterone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5-mg and 10-mg tablets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5−10mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Statins increase its plasma concentration. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medroxyprogesterone<a class="elsevierStyleCrossRef" href="#tblfn0050">d</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5-mg and 10-mg tablets \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5−10mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Administer in the first five days of the menstrual cycle. Does not appear to increase the risk of thrombosis. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Depo-Progevera [Depo-Provera] 150mg/ml ampoule. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Every three months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Does not appear to increase the risk of thrombosis. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Micronised progesterone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100-mg and 200-mg capsules \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">200−300mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">This medicine contains peanut and/or soybean oil and therefore should not be used in people with allergies to these foods. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Etonogestrel \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intradermal implant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68-mg implant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Every three years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Menstruation may continue up to three months after placement. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Levonorgestrel \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Intrauterine implant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Implant with an intrauterine release system of 0.02mg every 24h. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Every five years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Can cause headache \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Aromatase inhibitors</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Anastrozole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">May be beneficial in trans men with obesity and persistent menstruation. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Letrozole \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.5-mg tablet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.5mg/day \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:4 [ 0 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "a" "nota" => "Prior to testosterone therapy, it is advisable to measure ®-HCG (pregnancy test) and screen for sleep apnoea/hypopnoea syndrome (SAHS) with tools such as the STOP-BANG questionnaire." ] 1 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "b" "nota" => "Subcutaneous use (cypionate weekly): same preparation as IM, in which SC use is off-label. Increasingly used, as it yields more stable blood testosterone levels and possibly fewer side effects. It could be considered the route of choice if not for the inconvenience of weekly administration and the fact that it has to be drawn using an insulin or 1-ml syringe." ] 2 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "c" "nota" => "The use of testosterone gel in individuals under 18 years of age is off-label It should not be applied to the genital area (penis, testicles, clitoris or vulva) because its high alcohol content can cause local irritation." ] 3 => array:3 [ "identificador" => "tblfn0050" "etiqueta" => "d" "nota" => "Medroxyprogesterone. Precautions: it is necessary to take into account, as well as investigate in a timely manner, the history or appearance of the following conditions: migraine or unusual severe headache, acute visual alterations of any type, pathological changes in liver function or hormone levels." ] ] ] "descripcion" => array:1 [ "en" => "Hormonal preparations available for masculinising GAHT." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:29 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transgender medicine: best practices and clinical care for the future" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "V. Tangpricha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ecl.2019.03.001" "Revista" => array:7 [ "tituloSerie" => "Endocrinol Metab Clin North Am" "fecha" => "2019" "volumen" => "48" "numero" => "2" "paginaInicial" => "xv" "paginaFinal" => "xvii" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31655784" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La perspectiva de despatologización trans: ¿una aportación para enfoques de salud pública y prácticas clínicas en salud mental? Informe SESPAS 2020" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.S. Schwend" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.gaceta.2020.07.002" "Revista" => array:7 [ "tituloSerie" => "Gac Sanit" "fecha" => "2020" "volumen" => "34" "numero" => "Suppl 1" "paginaInicial" => "54" "paginaFinal" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32919815" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gender development and clinical presentation of gender nonconformity in children and adolescents. UpToDate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.D. Forcier" 1 => "M.D. Johanna Olson-Kennedy" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "WWW" => array:1 [ "link" => "https://www.uptodate.com/contents/gender-development-and-clinical-presentation-of-gender-diversity-in-children-and-adolescents" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gender is a multifaceted concept: evidence that specific life experiences differentially shape the concept of gender" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C. Mazzuca" 1 => "A. Majid" 2 => "L. Lugli" 3 => "R. Nicoletti" 4 => "A.M. Borghi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.31219/osf.io/ugv43" "Revista" => array:4 [ "tituloSerie" => "Lang Cogn" "fecha" => "2020" "paginaInicial" => "1" "paginaFinal" => "30" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Manual Diagnóstico y Estadístico De Los Trastornos Mentales (DSM-5)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "American Psychiatric Association (APA)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "5the ed." "fecha" => "2014" "editorial" => "Editorial Médica Panamericana" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transgender community belongingness as a mediator between strength of transgender identity and well-being" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.M. Barr" 1 => "S.L. Budge" 2 => "J.L. Adelson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1037/cou0000127" "Revista" => array:7 [ "tituloSerie" => "J Couns Psychol" "fecha" => "2016" "volumen" => "63" "numero" => "1" "paginaInicial" => "87" "paginaFinal" => "97" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26751157" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Percepción de la Salud y Relación con el Personal Sanitario. En: Informe “Las personas Trans y su relación con el sistema sanitario”" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Federación Española de lesbianas, gais, trans y bisexuales (FELGTB)" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2020" "editorial" => "Ministerio de Sanidad, Consumo y Bienestar Social" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global health burden and needs of transgender populations: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.L. Reisner" 1 => "T. Poteat" 2 => "J. Keatley" 3 => "M. Cabral" 4 => "T. Mothopeng" 5 => "E. Dunham" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(16)00684-X" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2016" "volumen" => "388" "numero" => "10042" "paginaInicial" => "412" "paginaFinal" => "436" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27323919" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.C. Hembree" 1 => "P.T. Cohen-Kettenis" 2 => "L. Gooren" 3 => "S.E. Hannema" 4 => "W.J. Meyer" 5 => "M.H. Murad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4158/1934-2403-23.12.1437" "Revista" => array:6 [ "tituloSerie" => "Endocr Pract" "fecha" => "2017" "volumen" => "23" "numero" => "12" "paginaInicial" => "1437" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29320642" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Standards of care for the health of transsexual, transgender, and gender-nonconforming people" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "World Professional Association for Transgender Health" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Libro" => array:4 [ "edicion" => "7th ed." "fecha" => "2012" "editorial" => "World Professional Association for Transgender Health" "editorialLocalizacion" => "Minneapolis" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://www.wpath.org/publications/soc" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for psychological practice with transgender and gender nonconforming people" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "American Psychological Association" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1037/a0039906" "Revista" => array:6 [ "tituloSerie" => "Am Psychol" "fecha" => "2015" "volumen" => "70" "paginaInicial" => "832" "paginaFinal" => "864" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26653312" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lesbian, gay, bisexual and transgender health: obstetrician-gynecologists’ training, attitudes, knowledge, and practice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.K. Mehta" 1 => "S.R. Easter" 2 => "J. Potter" 3 => "N. Castleberry" 4 => "J. Schulkin" 5 => "J.N. Robinson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/jwh.2017.6912" "Revista" => array:6 [ "tituloSerie" => "J Women’s Health" "fecha" => "2018" "volumen" => "27" "numero" => "12" "paginaInicial" => "1459" "paginaFinal" => "1495" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Barriers to gender-affirming care for transgender and gender nonconforming individuals" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.A. Puckett" 1 => "P. Cleary" 2 => "K. Rossman" 3 => "B. Mustanski" 4 => "M.E. Newcomb" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13178-017-0295-8" "Revista" => array:7 [ "tituloSerie" => "Sex Res Social Policy" "fecha" => "2017" "volumen" => "15" "numero" => "1" "paginaInicial" => "48" "paginaFinal" => "59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29527241" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transgender and gender nonconforming in emergency departments: a qualitative report of patient experiences" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Chisolm-Straker" 1 => "L. Jardine" 2 => "C. Bennouna" 3 => "N. Morency-Brassard" 4 => "L. Coy" 5 => "M.O. Egemba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/trgh.2016.0026" "Revista" => array:7 [ "tituloSerie" => "Transgend Health" "fecha" => "2017" "volumen" => "2" "numero" => "1" "paginaInicial" => "8" "paginaFinal" => "16" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28861544" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CIE-11 and the depathologisation of the transgender condition" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Robles García" 1 => "J.L. Ayuso-Mateos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rpsm.2019.01.002" "Revista" => array:7 [ "tituloSerie" => "Rev Psiquiatr Salud Ment (Engl Ed)" "fecha" => "2019" "volumen" => "12" "numero" => "2" "paginaInicial" => "65" "paginaFinal" => "67" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30846280" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Endocrinology of transgender medicine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. T’Sjoen" 1 => "J. Arcelus" 2 => "L. Gooren" 3 => "D.T. Klink" 4 => "V. Tangpricha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/er.2018-00011" "Revista" => array:8 [ "tituloSerie" => "Endocr Rev" "fecha" => "2019" "volumen" => "40" "numero" => "1" "paginaInicial" => "97" "paginaFinal" => "117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30307546" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1935861X16000024" "estado" => "S300" "issn" => "1935861X" ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ley Orgánica 10/1995, de 23 de noviembre, del Código Penal. [Accessed 10 December 2021]. Available from: <a target="_blank" href="https://www.boe.es/buscar/act.php?id=BOE-A-1995-25444">https://www.boe.es/buscar/act.php?id=BOE-A-1995-25444</a>." ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Toward a lowest effective dose of cyproterone acetate in trans women: results from the ENIGI study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S.M.E. Kuijpers" 1 => "C.M. Wiepjes" 2 => "E.B. Conemans" 3 => "A.D. Fisher" 4 => "G. T’Sjoen" 5 => "M. den Heijer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/clinem/dgab427" "Revista" => array:7 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2021" "volumen" => "106" "numero" => "10" "paginaInicial" => "e3936" "paginaFinal" => "e3945" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34125226" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacology of estrogens and progestogens: influence of different routes of administration" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "H. Kuhl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/13697130500148875" "Revista" => array:6 [ "tituloSerie" => "Climacteric" "fecha" => "2005" "volumen" => "8" "paginaInicial" => "3" "paginaFinal" => "63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16112947" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Weill" 1 => "P. Nguyen" 2 => "M. Labidi" 3 => "B. Cadier" 4 => "T. Passeri" 5 => "L. Duranteau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmj.n37" "Revista" => array:5 [ "tituloSerie" => "BMJ" "fecha" => "2021" "volumen" => "372" "paginaInicial" => "n37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33536184" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Report of the 2015 U.S. Transgender Survey" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S.E. Burnier James" 1 => "J.L. Herman" 2 => "S. Rankin" 3 => "M. Keisling" 4 => "L. Mottet" 5 => "M. Anafi" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2016" "editorial" => "National Center for Transgender Equality" "editorialLocalizacion" => "Washington, DC" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of endocrine disease: optimal feminizing hormone treatment in transgender people" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D. Glintborg" 1 => "G. T’Sjoen" 2 => "P. Ravn" 3 => "M.S. Andersen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-21-0059" "Revista" => array:7 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2021" "volumen" => "185" "numero" => "2" "paginaInicial" => "R49" "paginaFinal" => "R63" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34081614" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An approach to nonsuppressed testosterone in transgender women receiving gender-affirming feminizing hormonal therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Maheshwari" 1 => "T. Nippoldt" 2 => "C. Davidge-Pitts" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jendso/bvab068" "Revista" => array:6 [ "tituloSerie" => "J Endocr Soc" "fecha" => "2021" "volumen" => "5" "numero" => "9" "paginaInicial" => "bvab068" "itemHostRev" => array:3 [ "pii" => "S1474442218300322" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Capítulo 12. La sexualidad en la juventud" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Simón" 1 => "C. Clavería" 2 => "G. GarcíaAlbacete" 3 => "A. López Ortega" 4 => "M. Torre" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Libro" => array:5 [ "titulo" => "Informe. Juventud en España 2020" "fecha" => "2021" "paginaInicial" => "322" "paginaFinal" => "323" "editorial" => "Instituto de la Juventud (INJUVE)" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://www.injuve.es/sites/default/files/adjuntos/2021/03/informe_juventud_espana_2020.pdf" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hormonal treatment strategies tailored to non-binary transgender individuals" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C. Cocchetti" 1 => "J. Ristori" 2 => "A. Romani" 3 => "M. Maggi" 4 => "A.D. Fisher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/jcm9061609" "Revista" => array:6 [ "tituloSerie" => "J Clin Med" "fecha" => "2020" "volumen" => "9" "numero" => "6" "paginaInicial" => "1609" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32466485" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oestrogen and anti-androgen therapy for transgender women" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "V. Tangpricha" 1 => "M. den Heijer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-8587(16)30319-9" "Revista" => array:7 [ "tituloSerie" => "Lancet Diabetes Endocrinol" "fecha" => "2017" "volumen" => "5" "numero" => "4" "paginaInicial" => "291" "paginaFinal" => "300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27916515" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Testosterone therapy for transgender men" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.S. Irwig" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-8587(16)00036-X" "Revista" => array:7 [ "tituloSerie" => "Lancet Diabetes Endocrinol" "fecha" => "2017" "volumen" => "5" "numero" => "4" "paginaInicial" => "301" "paginaFinal" => "311" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27084565" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transexualidad: transiciones, detransiciones y arrepentimientos en España" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Pazos Guerra" 1 => "M. Gómez Balaguer" 2 => "M. Gomes Porras" 3 => "F. Hurtado Murillo" 4 => "E. Solá Izquierdo" 5 => "C. Morillas Ariño" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.endinu.2020.03.008" "Revista" => array:6 [ "tituloSerie" => "Endocrinol Diabetes Nutr" "fecha" => "2020" "volumen" => "67" "numero" => "9" "paginaInicial" => "562" "paginaFinal" => "567" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guías de práctica clínica para la valoración y tratamiento de la transexualidad. Grupo de Identidad y Diferenciación Sexual de la SEEN (GIDSEEN" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "O. Moreno-Pérez" 1 => "I. Esteva De Antonio" 2 => "Grupo de Identidad y Diferenciación Sexual de la SEEN (GIDSEEN)" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.endonu.2012.02.001" "Revista" => array:7 [ "tituloSerie" => "Endocrinol Nutr" "fecha" => "2012" "volumen" => "59" "numero" => "6" "paginaInicial" => "367" "paginaFinal" => "382" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22542505" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001652/v2_202304211110/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/25300180/00000070000000S1/v2_202304211110/S2530018022001652/v2_202304211110/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001652?idApp=UINPBA00004N"]

Statistics

Review article

Gender identity: Current concepts and gender-affirming hormone therapy

Identidad de género: Conceptos actuales y tratamiento hormonal de afirmación de género

Gilberto Pérez Lópeza,b

a Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, Spain

b Co-director del Curso Universitario Experto en Medicina Transgénero de la SEEN, Universidad de Barcelona, Editorial Panamericana, Spain

Read

1222

Times
was read the article

131

Total PDF

1091

Total HTML

Share statistics

 array:24 [
  "pii" => "S2530018022001652"
  "issn" => "25300180"
  "doi" => "10.1016/j.endien.2022.11.007"
  "estado" => "S300"
  "fechaPublicacion" => "2023-03-01"
  "aid" => "1305"
  "copyright" => "SEEN and SED"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:27-37"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S2530016422001185"
      "issn" => "25300164"
      "doi" => "10.1016/j.endinu.2022.02.007"
      "estado" => "S300"
      "fechaPublicacion" => "2023-03-01"
      "aid" => "1305"
      "copyright" => "SEEN y SED"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:27-37"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">REVISI&#211;N</span>"
        "titulo" => "Identidad de g&#233;nero&#58; Conceptos actuales y tratamiento hormonal de afirmaci&#243;n de g&#233;nero"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "27"
            "paginaFinal" => "37"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Gender identity&#58; Current concepts and gender-affirming hormone therapy"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1300
                "Ancho" => 2508
                "Tamanyo" => 283809
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Resumen de los conceptos m&#225;s relevantes relacionados con el g&#233;nero y la sexualidad&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Gilberto P&#233;rez L&#243;pez"
            "autores" => array:1 [
              0 => array:2 [
                "nombre" => "Gilberto"
                "apellidos" => "P&#233;rez L&#243;pez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2530018022001652"
          "doi" => "10.1016/j.endien.2022.11.007"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001652?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001185?idApp=UINPBA00004N"
      "url" => "/25300164/00000070000000S1/v3_202306211155/S2530016422001185/v3_202306211155/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2530018022001664"
    "issn" => "25300180"
    "doi" => "10.1016/j.endien.2022.11.008"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "1312"
    "copyright" => "SEEN and SED"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:38-50"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus document</span>"
      "titulo" => "Executive summary of the SEEN &#40;Sociedad Espa&#241;ola de Endocrinolog&#237;a y Nutrici&#243;n&#91;Spanish Society of Endocrinology and Nutrition&#93;&#41;-SEGO &#40;Sociedad Espa&#241;ola deGinecolog&#237;a y Obstetricia &#91;Spanish Society of Gynaecology and Obstetrics&#93;&#41; consensusdocument on the management of thyroid dysfunction during pregnancy"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "38"
          "paginaFinal" => "50"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Resumen ejecutivo del documento de consenso SEEN-SEGO sobre el manejo de la disfunci&#243;n tiroidea durante el embarazo"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1580
              "Ancho" => 2175
              "Tamanyo" => 228204
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Differential diagnosis of thyroid hyperfunction in the first trimester&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "In&#233;s Velasco, Llu&#237;s Vila, Maria Goya, Amelia Oleaga, Maria de la Calle, Fco&#46; Javier Santamaria"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "In&#233;s"
              "apellidos" => "Velasco"
            ]
            1 => array:2 [
              "nombre" => "Llu&#237;s"
              "apellidos" => "Vila"
            ]
            2 => array:2 [
              "nombre" => "Maria"
              "apellidos" => "Goya"
            ]
            3 => array:2 [
              "nombre" => "Amelia"
              "apellidos" => "Oleaga"
            ]
            4 => array:2 [
              "nombre" => "Maria"
              "apellidos" => "de la Calle"
            ]
            5 => array:2 [
              "nombre" => "Fco&#46; Javier"
              "apellidos" => "Santamaria"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S2530016422001410"
        "doi" => "10.1016/j.endinu.2022.03.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001410?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001664?idApp=UINPBA00004N"
    "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001664/v2_202304211110/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2530018022001640"
    "issn" => "25300180"
    "doi" => "10.1016/j.endien.2022.11.006"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "1290"
    "copyright" => "SEEN and SED"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Endocrinol Diabetes Nutr. 2023;70 Supl 1:7-26"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus document</span>"
      "titulo" => "Consensus document on the management of hyponatraemia of the Acqua Group of the Spanish Society of Endocrinology and Nutrition"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "7"
          "paginaFinal" => "26"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Documento de consenso sobre el manejo de la hiponatremia del Grupo Acqua de la Sociedad Espa&#241;ola de Endocrinolog&#237;a y Nutrici&#243;n"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0025"
          "etiqueta" => "Figure 5"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr5.jpeg"
              "Alto" => 1613
              "Ancho" => 2343
              "Tamanyo" => 351727
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0025"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Adjustment protocol for outpatient tolvaptan treatment in patients with syndrome of inappropriate ADH secretion &#40;SIADH&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">65</span></a></p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">NaS&#58; serum sodium&#59; GS&#58; glucose serum&#59; TV&#58; tolvaptan&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "David E&#46; Barajas Galindo, Jorge Gabriel Ruiz-S&#225;nchez, Alberto Fern&#225;ndez Mart&#237;nez, Isabelle Runkle de la Vega, Juan Carlos Ferrer Garc&#237;a, Guillermo Ropero-Luis, Ana Ortol&#225; Buigues, Joaqu&#237;n Serrano Gotarredona, Emilia G&#243;mez Hoyos"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "David E&#46;"
              "apellidos" => "Barajas Galindo"
            ]
            1 => array:2 [
              "nombre" => "Jorge Gabriel"
              "apellidos" => "Ruiz-S&#225;nchez"
            ]
            2 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Fern&#225;ndez Mart&#237;nez"
            ]
            3 => array:2 [
              "nombre" => "Isabelle Runkle"
              "apellidos" => "de la Vega"
            ]
            4 => array:2 [
              "nombre" => "Juan Carlos"
              "apellidos" => "Ferrer Garc&#237;a"
            ]
            5 => array:2 [
              "nombre" => "Guillermo"
              "apellidos" => "Ropero-Luis"
            ]
            6 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Ortol&#225; Buigues"
            ]
            7 => array:2 [
              "nombre" => "Joaqu&#237;n"
              "apellidos" => "Serrano Gotarredona"
            ]
            8 => array:2 [
              "nombre" => "Emilia"
              "apellidos" => "G&#243;mez Hoyos"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S2530016422001045"
        "doi" => "10.1016/j.endinu.2022.01.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016422001045?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001640?idApp=UINPBA00004N"
    "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001640/v2_202304211110/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
    "titulo" => "Gender identity&#58; Current concepts and gender-affirming hormone therapy"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "27"
        "paginaFinal" => "37"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Gilberto P&#233;rez L&#243;pez"
        "autores" => array:1 [
          0 => array:4 [
            "nombre" => "Gilberto"
            "apellidos" => "P&#233;rez L&#243;pez"
            "email" => array:1 [
              0 => "gperezl@salud.madrid.org"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servicio de Endocrinolog&#237;a y Nutrici&#243;n&#44; Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Co-director del Curso Universitario Experto en Medicina Transg&#233;nero de la SEEN&#44; Universidad de Barcelona&#44; Editorial Panamericana&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Identidad de g&#233;nero&#58; Conceptos actuales y tratamiento hormonal de afirmaci&#243;n de g&#233;nero"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1309
            "Ancho" => 2478
            "Tamanyo" => 292189
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0030"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of the most important concepts related to gender and sexuality&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">As trans people have made advances in their legitimate rights&#44; they have gained greater relevance in the health field&#46; Healthcare for trans people requires a holistic approach in which the endocrinologist plays a crucial role in coordinating and covering all the needs of these people&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">More generally&#44; research on the health of transgender people continues to tend to represent this group as somewhat homogeneous and lacking in diversity in areas such as ethnicity&#44; gender identity and sexuality&#44; when in clinical practice we find complexity and heterogeneity&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Transgender medicine<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> is a new field of medical knowledge concerned with the multidisciplinary care of trans people&#44; from a depathologising perspective&#44;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> in order to achieve the best standards of health&#46; This increased interest in transgender medicine is due in large part to heightened awareness of the medical needs of transgender people in the healthcare setting&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Advances in transgender medicine&#44; the complexity of diverse trans identities and the impact of hormone therapy on the quality of life and risk of middle- and long-term complications in trans people force us to examine in more detail an individualised biopsychosocial approach that requires specific training in this area of knowledge&#44; as well as updating on the concepts&#44; terminology and drug treatments used&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Relevant concepts in transgender medicine</span><p id="par0025" class="elsevierStylePara elsevierViewall">Each individual is a composite of gender and sexuality &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; Both concepts have a biological component and a social construct&#46; But it is these two basic concepts that usually cause enormous confusion&#44; so it is necessary to establish the differences between them&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">Gender<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> refers to the social attributes and opportunities associated with being a man or a woman&#44; and the relationships between men and women&#44; and boys and girls&#46; These attributes&#44; opportunities and relationships are established and learned in society&#44; are context- and time-specific&#44; and may change &#8212; they are dynamic &#40;for example&#44; more and more men do housework&#41;&#46; Gender determines what is expected&#44; permitted and valued in a man or woman in a given context&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">In more academic terms&#44; we can identify three components of gender<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#9633;</span><p id="par0040" class="elsevierStylePara elsevierViewall">Gender identity</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#9633;</span><p id="par0045" class="elsevierStylePara elsevierViewall">Gender expression</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#9633;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Biological sex</p></li></ul></p><p id="par0055" class="elsevierStylePara elsevierViewall">Gender identity<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;4</span></a> refers to the inner individual experience of gender&#44; as each person deeply feels it&#44; which may or may not correspond to the sex assigned at birth&#44; including the personal experience of the body&#46; This experience of gender is intimate&#44; diverse and complex&#44; and answers the question &#34;Who am I&#63;&#34;&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">Gender identity was previously considered as something dichotomous or binary &#40;male or female&#41;&#44; but nowadays it is understood as a spectrum where being a man or a woman are the extremes and in between there are different identities&#46; This is called non-binary gender&#58; a spectrum of gender identities and expressions stemming from a rejection of the binary assumption of gender as a strictly exclusive choice between man&#47;male&#47;masculine or woman&#47;female&#47;feminine&#44; based upon the sex assigned at birth&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5&#44;6</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">The terms &#34;cisgender&#34; and &#34;transgender&#34; are used to describe the congruence or incongruence of one&#39;s felt gender identity with one&#39;s sex assigned at birth&#46; Cisgender &#40;the prefix <span class="elsevierStyleItalic">cis</span> is commonly used as a short form&#41; describes a person whose gender identity is consistent with their sex assigned at birth&#46; Transgender &#40;the prefix <span class="elsevierStyleItalic">trans</span> is commonly used as a short form&#41; is an umbrella term used to describe a person whose gender identity does not correspond with their sex assigned at birth&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">Gender expression refers to a person&#39;s outward presentation of gender&#44; and includes personal style&#44; dress&#44; hair&#44; make-up&#44; jewellery&#44; vocal inflection and body language&#46; It is typically categorised as feminine&#44; masculine or androgynous&#46; All people express a gender&#46; It may be consistent or inconsistent with a person&#39;s gender identity&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">Strictly speaking&#44; the term sex<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> refers to&#58; the biological differences between men and women&#59; their physiological characteristics&#59; the sum of the biological characteristics that define the spectrum of humans as women or men&#59; and the biological construct that refers to the genetic&#44; hormonal&#44; anatomical and physiological characteristics based upon which a person is classified as male or female at birth&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Sexuality is a central aspect of human beings that is present throughout their lives&#46; It encompasses gender roles&#44; sexual orientation&#44; eroticism&#44; pleasure&#44; intimacy and reproduction&#46; It is felt and expressed through thoughts&#44; fantasies&#44; desires&#44; beliefs&#44; attitudes&#44; values&#44; behaviours&#44; practices&#44; roles and relationships&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">While sexuality<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;4</span></a> may include all of these dimensions&#44; not all of them are always experienced or expressed&#46; Sexuality is influenced by the interaction of biological&#44; psychological&#44; social&#44; economic&#44; political&#44; cultural&#44; ethical&#44; legal&#44; historical&#44; religious and spiritual factors&#46; Sexuality includes one of the concepts that creates the most confusion in healthcare and social settings&#58; sexual orientation&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">An individual&#39;s sexual orientation<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#44;5</span></a> is independent of their biological sex or gender identity&#46; It has been defined as each person&#39;s ability to feel a deep emotional&#44; affective and sexual attraction for people of a gender other than their own&#44; or of the same gender&#44; or of more than one gender&#44; as well as the ability to maintain intimate and sexual relationships with these people&#46; The terms heterosexuality&#44; homosexuality and bisexuality come under the heading of sexual orientation&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Transgender medicine terminology</span><p id="par0095" class="elsevierStylePara elsevierViewall">Concepts related to gender identity have evolved at great speed in recent years&#46; These concepts are dynamic&#44; so constant updating is required&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Given the increased demand for healthcare from trans people&#44; it is necessary to use a uniform language that enables people with different trans identities to be treated in a dignified and non-pathologising way&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">According to the 2020 report &#34;Las personas trans y su relaci&#243;n con el sistema sanitario&#34;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> &#91;Trans people and their relationship with the healthcare system&#93; from the Federaci&#243;n Espa&#241;ola de Lesbianas&#44; Gais&#44; Trans y Bisexuales &#40;FELGTB&#41; &#91;Spanish Federation of Lesbian&#44; Gay&#44; Trans and Bisexual People&#93;&#41;&#44; 48&#37; of trans people reported having experienced discriminatory or inappropriate treatment from healthcare staff&#44; and the majority of them reported that said professionals were not aware of current gender identity-related terminology&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> lists the most important concepts and commonly used terminology in gender identity consultations&#44; which are necessary for establishing adequate communication and a good doctor-user relationship&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#8211;15</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Gender-affirming hormone therapy</span><p id="par0115" class="elsevierStylePara elsevierViewall">Endocrinologists are called upon to coordinate the comprehensive care of trans people and&#44; therefore&#44; we are responsible for part of the medical transition&#44; which includes gender-affirming hormone therapy &#40;GAHT&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> GAHT is the use of hormonal and non-hormonal medicines to achieve physical changes consistent with the patient&#39;s felt gender identity &#40;binary or non-binary&#41; as part of a gender-affirmative approach&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Starting GAHT is an important step for trans people and requires a prior biopsychosocial assessment&#44; which enables the endocrinologist to prescribe safe treatment agreed upon with the person who wishes to start transitioning&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Most of Spain&#39;s Autonomous Communities &#40;ACs&#41; have laws protecting trans people that regulate and govern&#44; among other things&#44; the healthcare of these people&#46; In the absence of a nationwide trans law&#44; most ACs recognise gender self-identification &#40;including Madrid&#44; Andalusia and the Valencian Community&#41;&#44; so a psychological&#47;psychiatric report prior to GAHT is not needed &#40;in much of the country&#41;&#44; but psychological support is offered&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">On 29 June 2021&#44; the Spanish Council of Ministers presented a draft bill for the real and effective equality of trans people and for the guarantee of the rights of LGBTI people&#44; which is under consideration and seeks to harmonise healthcare for trans people across Spain&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">During a person&#39;s transition&#44; it is necessary not only to prescribe treatment but also to support them&#44; monitor the safety and efficacy of the treatment and guide them towards achieving the appearance with which they really identify&#46; Informed consent &#40;IC&#41; must be obtained before GAHT is initiated&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">IC is not just a patient&#47;user right&#44; it is also a mechanism that gives legal protection to endocrinologists prescribing GAHT&#46; In the case of minors or people with disabilities&#44; the consent form must be signed by BOTH parents or legal guardians &#40;Spanish Penal Code&#58; articles 155 and 156&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> It must be remembered that even if a parent does not have custody&#44; they almost always retain parental authority&#46; If one of the parents&#47;guardians does not give their consent for the treatment&#44; the GAHT cannot be started&#44; since that would contravene the penal code&#46; In this last circumstance in which the parents disagree&#44; the final decision must be taken by a juvenile court&#44; based on the best interests of the minor&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The free&#44; conscious desire of the trans person to start hormone therapy is not enough to initiate GAHT&#59; they must also not have any serious clinical or psychiatric conditions that put their own health or adequate compliance with treatment at risk&#46; In this regard&#44; it is very important not to fall into downplaying or exaggerating the risks involved&#46; The latter &#40;magnifying the risks associated with hormone therapy&#41; is sometimes a major obstacle when starting GAHT&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Contraindications to this treatment can be classified according to the type of GAHT<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10&#44;16</span></a>&#58;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Feminising GAHT&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#9633;</span><p id="par0160" class="elsevierStylePara elsevierViewall">Active oestrogen-sensitive cancer &#40;absolute contraindication&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#9633;</span><p id="par0165" class="elsevierStylePara elsevierViewall">Unstable ischaemic heart disease &#40;absolute contraindication&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#9633;</span><p id="par0170" class="elsevierStylePara elsevierViewall">Severe cerebrovascular disease &#40;stroke&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#9633;</span><p id="par0175" class="elsevierStylePara elsevierViewall">Thrombophilia &#40;hereditary or acquired&#41; and&#47;or history of thromboembolic events&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">&#9633;</span><p id="par0180" class="elsevierStylePara elsevierViewall">Prolactinoma &#40;prolactin-producing pituitary adenoma&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">&#9633;</span><p id="par0185" class="elsevierStylePara elsevierViewall">Uncontrolled psychosis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">&#9633;</span><p id="par0190" class="elsevierStylePara elsevierViewall">Poorly controlled diabetes&#46;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">&#9633;</span><p id="par0195" class="elsevierStylePara elsevierViewall">Severe kidney or liver disease&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">&#9633;</span><p id="par0200" class="elsevierStylePara elsevierViewall">Severe hypertriglyceridaemia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">&#9633;</span><p id="par0205" class="elsevierStylePara elsevierViewall">Psychiatric conditions that limit the ability to provide informed consent&#46;</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">&#9633;</span><p id="par0210" class="elsevierStylePara elsevierViewall">Hypersensitivity &#40;allergy&#41; to one of the ingredients of the oestrogen formulation or other hormone preparations&#46;</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">&#9633;</span><p id="par0215" class="elsevierStylePara elsevierViewall">Those with a strong family history of breast and&#47;or ovarian cancer should be referred for genetic counselling to undergo screening for familial cancer in order to clarify their individual risk&#46;</p></li></ul></p><p id="par0220" class="elsevierStylePara elsevierViewall">Masculinising GAHT&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">&#9633;</span><p id="par0225" class="elsevierStylePara elsevierViewall">Pregnancy or breastfeeding &#40;absolute contraindication&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">&#9633;</span><p id="par0230" class="elsevierStylePara elsevierViewall">Active androgen-sensitive cancer &#40;absolute contraindication&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">&#9633;</span><p id="par0235" class="elsevierStylePara elsevierViewall">Unstable ischaemic heart disease&#46;</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">&#9633;</span><p id="par0240" class="elsevierStylePara elsevierViewall">Severe cerebrovascular disease &#40;stroke&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">&#9633;</span><p id="par0245" class="elsevierStylePara elsevierViewall">Thrombophilia &#40;hereditary or acquired&#44; such as that associated with antiphospholipid syndrome&#41; and&#47;or history of thromboembolic events&#46;</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">&#9633;</span><p id="par0250" class="elsevierStylePara elsevierViewall">Active endometrial cancer&#46;</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">&#9633;</span><p id="par0255" class="elsevierStylePara elsevierViewall">Uncontrolled psychosis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">&#9633;</span><p id="par0260" class="elsevierStylePara elsevierViewall">Poorly controlled diabetes&#46;</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">&#9633;</span><p id="par0265" class="elsevierStylePara elsevierViewall">Severe kidney or liver disease&#46;</p></li><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">&#9633;</span><p id="par0270" class="elsevierStylePara elsevierViewall">Severe hypertriglyceridaemia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">&#9633;</span><p id="par0275" class="elsevierStylePara elsevierViewall">Psychiatric conditions that limit the ability to provide informed consent&#46;</p></li><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">&#9633;</span><p id="par0280" class="elsevierStylePara elsevierViewall">Hypersensitivity &#40;allergy&#41; to one of the ingredients of the testosterone formulation or other hormone preparations&#46;</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">&#9633;</span><p id="par0285" class="elsevierStylePara elsevierViewall">Those patients with a strong family history of breast and&#47;or ovarian cancer should be referred for genetic counselling to undergo screening for familial cancer in order to clarify their individual risk&#46;</p></li></ul></p><p id="par0290" class="elsevierStylePara elsevierViewall">Most of these contraindications are relative&#44; in the sense that they require clinical stabilisation &#40;controlling diabetes&#44; decreasing triglycerides or waiting at least six months after a major cardiovascular event&#41; before being able to start hormone therapy&#46; They delay GAHT&#44; but do not contraindicate it from the outset&#46;</p><p id="par0295" class="elsevierStylePara elsevierViewall">As regards complementary tests before starting GAHT&#44; generally speaking&#44; apart from laboratory tests &#40;complete blood count&#44; biochemical and basic clotting tests&#44; gonadal profile&#41;&#44; other complementary tests &#40;such as karyotype test&#44; thrombophilia test and breast&#47;pelvic ultrasound&#41; are not routinely recommended&#44;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10</span></a> unless the medical history&#44; personal or family history and&#47;or physical examination suggest the existence of comorbidities&#46;</p><p id="par0300" class="elsevierStylePara elsevierViewall">Ordering unjustified complementary tests is one of the factors that delay the start of hormone therapy and increase healthcare costs&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">General considerations</span><p id="par0400" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">1&#41;</span><p id="par0305" class="elsevierStylePara elsevierViewall">The goals of gender-affirming hormone therapy &#40;GAHT&#41; in trans people are determined by various factors&#44; including&#58; age&#44; ability to consent to treatment&#44; pre-existing health problems&#44; risk of future development of diseases&#44; access to care and user desire during the transition&#46;</p></li><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">2&#41;</span><p id="par0310" class="elsevierStylePara elsevierViewall">Trans people should be asked about gamete preservation before starting GAHT and given advice and guidance on realistic expectations of masculinisation&#47;feminisation&#44; and when such changes will begin to occur&#46;</p></li><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">3&#41;</span><p id="par0315" class="elsevierStylePara elsevierViewall">The first consultation should include identification of potential risks for GAHT&#58; smoking&#44; alcohol consumption and risk behaviours&#44; family history of cancer &#40;gynaecological&#44; breast and prostate&#41;&#44; cardiovascular disease&#44; diabetes&#44; hypertension and dyslipidaemia&#46;</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">4&#41;</span><p id="par0320" class="elsevierStylePara elsevierViewall">It is advisable to offer psychological support to manage expectations before&#44; during and after transitioning&#46;</p></li><li class="elsevierStyleListItem" id="lsti0165"><span class="elsevierStyleLabel">5&#41;</span><p id="par0325" class="elsevierStylePara elsevierViewall">Physical examination &#40;of the breasts and genitals&#41; can cause anxiety and discomfort&#59; it must always be performed only with the explicit consent of the person and be approached in a sensitive&#44; respectful manner&#46;</p></li><li class="elsevierStyleListItem" id="lsti0170"><span class="elsevierStyleLabel">6&#41;</span><p id="par0330" class="elsevierStylePara elsevierViewall">Signed inform consent must always be obtained &#40;in the case of minors under 18 years of age and people with intellectual disabilities&#44; the consent form must also be signed by both parents and&#47;or legal guardians&#41;&#46;</p></li></ul></p><p id="par0335" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRefs" href="#tbl0010">Tables 2 and 3</a> summarise the hormone preparations commonly used in masculinising and feminising GAHT&#44;<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18&#8211;27</span></a> including some important comments on their safety&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0340" class="elsevierStylePara elsevierViewall">The initiation of gender-affirming hormone therapy is as important as follow-up to ensure changes occur at a timely pace&#44; to adjust treatment&#44; and to monitor&#47;identify any related adverse effects&#46;</p><p id="par0345" class="elsevierStylePara elsevierViewall">Although the various guidelines recommend variable follow-up times&#44; they all agree that most of the serious adverse effects associated with GAHT occur in the first year&#44; so a check-up every three to six months is recommended&#46; In any case&#44; it should be clarified that most of those recommendations &#40;which include GAHT&#41; are based on evidence that is of low quality or has not been directly established at the present time&#44; and the drugs are used off-label&#46;<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26&#44;27</span></a> Therefore&#44; these are high-priority research areas&#46;</p><p id="par0350" class="elsevierStylePara elsevierViewall">The demand for GAHT has increased in recent years&#44; mostly driven by adolescents and young adults&#46; Meanwhile&#44; there is a minority of people on GAHT who may ask to detransition<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a>&#58; a procedure to reverse the changes made in the gender reassignment process&#44; whether medical&#44; social or administrative&#46; Detransitioning may or may not be associated with identity desistance&#46;</p><p id="par0355" class="elsevierStylePara elsevierViewall">However&#44; it is believed that the existence of cases of detransitioning does not invalidate the need for public&#44; specialised healthcare for these people&#44; from which the majority clearly benefit&#44; with psychological support being a useful tool throughout the transitioning process&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">GAHT in non-binary trans people</span><p id="par0360" class="elsevierStylePara elsevierViewall">The few existing studies<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> have indicated that non-binary trans people represent 25&#8722;35&#37; of trans people attending transgender medicine consultations&#46; In Spain&#44;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> one in four people under the age of 30 identifies with a non-binary identity&#46;</p><p id="par0365" class="elsevierStylePara elsevierViewall">What they want from GAHT can range from the complete loss of secondary sexual characteristics &#40;demasculinisation or defeminisation&#41; to the complete acquisition of the appearance of the felt gender identity&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> In this regard&#44; there may even be people who do not need GAHT to transition &#40;agender or bigender&#41;&#46;</p><p id="par0370" class="elsevierStylePara elsevierViewall">Being aware of the reality of this group is key to providing adequate care in transgender medicine consultations&#46; Before indicating GAHT in this group&#44; it is very important to know the desires and expectations of each person in depth&#58; to individualise&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Conclusions</span><p id="par0375" class="elsevierStylePara elsevierViewall">Transgender healthcare is a rapidly growing field&#44; with an exponential increase in published research in recent years&#46; Research and practice in transgender medicine have not always been sensitive to trans people&#44; since most studies have focused on a biological cause rather than on improving their health&#46;</p><p id="par0380" class="elsevierStylePara elsevierViewall">At present&#44; there are high-priority research topics in this field&#44; such as the causes of excess morbidity and mortality&#44; cardiovascular risk and cancer&#44; the impact of GAHT on mental health&#44; ageing&#44; and sexual and reproductive health&#46; Urgent updates are also needed to Spanish clinical practice guidelines<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> for managing gender identity&#44; since the existing ones have become outdated and&#44; in some respects&#44; run contrary to the current approach to sexual and gender diversity&#46;</p><p id="par0385" class="elsevierStylePara elsevierViewall">Advances in transgender medicine&#44; the complexity of diverse trans identities&#44; the impact of hormone therapy on quality of life and the risk of medium and long-term complications for trans people force us to study in more detail an individualised biopsychosocial approach&#46; Endocrinologists have historically been at the forefront of hormone therapy&#44; but as the demand&#44; diversity and complexity of our users increase&#44; we need to be able to offer a holistic view of their needs&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Funding</span><p id="par0390" class="elsevierStylePara elsevierViewall">I have not received any funding for this review&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Conflicts of interest</span><p id="par0395" class="elsevierStylePara elsevierViewall">The author declares that he&#47;she has no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1887358"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1634486"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1887359"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1634485"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Relevant concepts in transgender medicine"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Transgender medicine terminology"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Gender-affirming hormone therapy"
        ]
        8 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "General considerations"
        ]
        9 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "GAHT in non-binary trans people"
        ]
        10 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conclusions"
        ]
        11 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Funding"
        ]
        12 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflicts of interest"
        ]
        13 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-02"
    "fechaAceptado" => "2022-02-06"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1634486"
          "palabras" => array:6 [
            0 => "Transgender"
            1 => "Cisgender"
            2 => "Transition"
            3 => "Gender-affirming hormone therapy"
            4 => "Nonbinary gender"
            5 => "Transgender medicine"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1634485"
          "palabras" => array:6 [
            0 => "Transg&#233;nero"
            1 => "Cisg&#233;nero"
            2 => "Transici&#243;n"
            3 => "Tratamiento hormonal de afirmaci&#243;n de g&#233;nero"
            4 => "G&#233;nero no binario"
            5 => "Medicina transg&#233;nero"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">In the past five years&#44; healthcare organisation for trans people in Spain has changed as laws intended to protect sexual and gender diversity have been put in place&#46; As a result&#44; endocrinologists are not only on the front lines &#40;understood as prescribing and following up gender-affirming hormone therapy&#41; but also coordinating multidisciplinary healthcare for these individuals&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Advances in transgender medicine&#44; the complexity of diverse trans identities and the impact of hormone therapy on quality of life and risk of middle- and long-term complications call for in-depth examination of a personalised biopsychosocial approach to trans people that requires specific training in this field of knowledge as well as updates on the concepts&#44; terminology and drug treatments used&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">En los &#250;ltimos 5 a&#241;os la organizaci&#243;n de la atenci&#243;n sanitaria a las personas Trans en Espa&#241;a ha cambiado en la medida que se han puesto en marcha leyes que tienen como objetivo la protecci&#243;n de la diversidad sexual y de g&#233;nero&#46; Esto ha hecho que los endocrin&#243;logos no s&#243;lo estemos en la primera l&#237;nea &#40;entendida como la prescripci&#243;n y seguimiento del tratamiento hormonal de afirmaci&#243;n de g&#233;nero&#41; sino que adem&#225;s coordinemos la atenci&#243;n sanitaria multidisciplinar de estas personas&#46;</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">El avance de la Medicina Transg&#233;nero&#44; la complejidad de las diversas identidades Trans as&#237; como el impacto del tratamiento hormonal en la calidad de vida y en el riesgo de complicaciones a medio y largo plazo&#44; nos obliga a profundizar en un abordaje bio-psico-social e individualizado de las personas Trans que requiere de una formaci&#243;n espec&#237;fica en esta &#225;rea de conocimiento as&#237; como de la actualizaci&#243;n de los conceptos&#44; terminolog&#237;a y tratamientos farmacol&#243;gicos utilizados&#46;</p></span>"
      ]
    ]
    "multimedia" => array:4 [
      0 => array:8 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1309
            "Ancho" => 2478
            "Tamanyo" => 292189
          ]
        ]
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0030"
            "detalle" => "Figure "
            "rol" => "short"
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of the most important concepts related to gender and sexuality&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0035"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">ICD&#58; International Classification of Diseases&#44; published by the World Health Organization&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Concept&#47;terms&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Definition&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Trans depathologisation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A theoretical&#47;activist perspective that&#44; rather than conceptualising gender diversity as a mental disorder&#44; defends the recognition and protection of gender expression and identity as human rights&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LGBTQI&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">An initialism used as an umbrella term that attempts to encompass all genders and sexual minorities as well as identities outside of the cisgender and heteronormative binaries&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender dysphoria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">According to the DSM-5&#44; clinically significant distress from incongruence between felt gender identity and sex assigned at birth&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transsexualism&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">According to the ICD-10&#44; it is the desire to live and be accepted as a member of the opposite sex&#44; which is often accompanied by feelings of discomfort or disagreement with one&#39;s own anatomical sex and the desire to undergo surgery or hormone therapy to make one&#39;s own body match the preferred sex as closely as possible&#46; Term in disuse &#40;currently the ICD-11 is in force&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transsexuality&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">According to the ICD-10&#44; a concept that indicates congruence between biological sex as defined by genitalia assigned at birth with conviction of being and identification with the opposite gender&#46; Term in disuse &#40;the ICD-11 is currently in force&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transsexual&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A person who has feelings of being born with the wrong physical sex&#46; This term is also used to describe a person who presents physical changes due to hormone therapy and&#47;or surgery&#46; The use of this term is not recommended &#40;transgender or trans are preferred&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender incongruence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">According to the ICD-11&#44; it is the marked&#44; persistent incongruence or lack of conformity between a person&#39;s experienced gender and assigned sex&#44; which often leads to a desire to transition in order to live and be accepted as a person of the experienced gender&#46; The terms gender mismatch&#44; gender discomfort and gender nonconforming are commonly used as synonyms&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Binary gender&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">It is the idea that gender is a strict choice between man&#47;male&#47;masculine and woman&#47;female&#47;feminine&#44; based on the sex assigned at birth&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Non-binary gender&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A spectrum of gender identities and expressions based on the rejection of the binary assumption of gender as a strictly exclusive choice between man&#47;male&#47;masculine and woman&#47;female&#47;feminine&#44; based on the sex assigned at birth&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Misgendering</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A term used when somebody identifies a trans person with a gender other than their felt gender&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Deadname</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A term that refers to the name given at birth to a trans or non-binary person before they assumed their current gender identity &#40;or any name with which they previously identified&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Deadnaming</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">The act of calling a person by the name given to them by their parents or legal guardians at birth&#44; and not by their felt name&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender self-identification&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A process in which a person legally and freely recognises their gender identity through an express declaration&#44; with no need to present a medical diagnosis or meet any other requirement&#44; such as the presence of witnesses&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psychological support&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psychotherapy is viewed as a facilitating intervention in the process of personal growth and the development of one&#39;s own psychic autonomy&#44; not as a technique for curing or diagnosing any type of mental disorder&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender-affirming approach&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">An approach to gender identity in social and healthcare settings that respects and accepts people&#39;s gender self-identification&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transitioning&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A process by which a person outwardly manifests their felt gender identity&#46; While unique to each individual&#44; the ultimate goal of transitioning is to be able to be seen&#44; known and related to according to the core experience of self&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender-affirming hormone therapy &#40;GAHT&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">The use of hormonal and non-hormonal medications to achieve physical changes consistent with the felt gender identity &#40;binary or non-binary&#41; based on the gender-affirmative approach&#46; It is recommended that gender-affirming hormone therapy be used instead of cross-sex hormone therapy&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gender-affirming surgery&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Surgical procedures that align physical characteristics with the felt gender&#46; This term is now preferred over sex reassignment surgery&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Basic concepts in transgender medicine and commonly used terminology&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0040"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">GAHT&#58; gender-affirming hormone therapy&#59; SL&#58; sublingual&#59; IM&#58; intramuscular&#59; SC&#58; subcutaneous&#59; DVT&#58; deep vein thrombosis&#59; AMAB&#58; assigned male at birth&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">ACs&#58; Autonomous Communities&#59; DVT&#58; deep vein thrombosis&#59; CHF&#58; congestive heart failure&#59; PSA&#58; prostate specific antigen&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_colgroup " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Antiandrogens</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Type&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">GnRH analogues</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Triptorelin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;75-mg and 7&#46;25-mg vial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;75<span class="elsevierStyleHsp" style=""></span>mg&#47;28 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Good tolerance&#46; Commonly used in adults in the United Kingdom and the Netherlands&#46; In Spain&#44; it is used in a minority of cases due to its price&#44; although it is subsidised by some ACs&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;25<span class="elsevierStyleHsp" style=""></span>mg&#47;3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">May prolong QT interval&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Progestogens</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cyproterone acetate<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&#46;5&#8722;25<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibits secretion of gonadotropins and blocks androgen receptors&#46; Assess its contraindications&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dienogest&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;3<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Progestagen with antiandrogen activity &#40;40&#8211;60&#37; compared to cyproterone&#41;&#46; Preferably use in combination with oestradiol valerate &#40;some combinations contain ethinyloestradiol&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Drospirenone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;5-mg and 3-mg tablets&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;5&#8722;3<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Progestagen with antiandrogen activity &#40;40&#8722;60&#37; compared to cyproterone&#41; and aldosterone antagonist &#40;as it is derived from spironolactone&#46; Preferably used in combination with oestradiol valerate &#40;some combinations contain ethinyloestradiol&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Androgen receptor antagonists</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Spironolactone<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25-mg and 100-mg tablets&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#8722;400<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Monitor blood pressure&#46; Inexpensive&#46; Risk of liver toxicity&#46; Diarrhoea and rash&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Flutamide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">250-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">250&#8722;500<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;1&#8722;2 doses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Risk of liver toxicity and thromboembolic disease&#46; Increases oestradiol &#40;increased risk of DVT&#41;&#46; Adjust dose of oestrogens and anticoagulants&#46; May prolong QT interval&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bicalutamide<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25&#8722;50<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated in interstitial lung disease&#46; Liver toxicity&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">5&#945;-reductase inhibitors</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Finasteride&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Useful following gonadectomy&#46; Contains lactose&#46; Monitor PSA&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dutasteride&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;5-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interaction with ritonavir&#47;indinavir and calcium channel blockers&#46; Monitor PSA&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
            1 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Feminising preparations</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Micronised oestradiol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&#47;sublingual&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-mg tablets&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&#58; 2&#8722;4<span class="elsevierStyleHsp" style=""></span>mg&#47;day in two doses&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Of choice when starting GAHT&#58; a plasma oestrone-to-oestradiol ratio of 5&#58;1 promotes breast bud formation&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oestradiol valerate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&#47;sublingual&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-mg and 2-mg tablets in combination with progestagens&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SL&#58; 0&#46;5&#8722;4<span class="elsevierStyleHsp" style=""></span>mg&#47;day in two doses&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">The sublingual route &#40;as an alternative to the transdermal or intramuscular&#47;subcutaneous route&#41; is recommended from Tanner stage 3&#8722;4 of breast development to promote glandular hyperplasia&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&#47;SC<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ampoules in concentrations of 5&#44; 20 and 40<span class="elsevierStyleHsp" style=""></span>mg&#47;ml&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;4<span class="elsevierStyleHsp" style=""></span>mg weekly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#37; bioavailability&#46; Achieves suppression of testosterone secretion without requiring antiandrogens&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ethinyloestradiol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;02&#8722;0&#46;03<span class="elsevierStyleHsp" style=""></span>mg tablets combined with progestagens&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;02&#8722;0&#46;03<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;20&#8722;30<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;day&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Always as a last resort&#58; Increased risk of DVT&#46; In regular clinical practice&#44; it is not possible to measure plasma levels&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transdermal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Extended-release patch&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&#46;9<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;24<span class="elsevierStyleHsp" style=""></span>h in combination with progestagens &#40;for 7 days&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oestradiol hemihydrate &#40;patches&#41;<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transdermal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Patches of 25&#44; 50&#44; 75 and 100<span class="elsevierStyleHsp" style=""></span>&#956;g&#47;24<span class="elsevierStyleHsp" style=""></span>h &#40;for 3&#8722;4 days&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#8722;200 &#956;g&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Low risk of DVT&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oestradiol hemihydrate &#40;gel&#41;<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gel at a concentration of 0&#46;6<span class="elsevierStyleHsp" style=""></span>mg&#47;g&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8722;6<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oestradiol hemihydrate &#40;spray&#41;<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Each spray administers 1&#46;53<span class="elsevierStyleHsp" style=""></span>mg&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#8722;9<span class="elsevierStyleHsp" style=""></span>mg&#47;day &#40;in 2&#8722;3 doses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Low risk of DVT&#46; With this formulation&#44; lower oestradiol peaks are obtained &#8211; up to 60&#37; less &#40;versus gel&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Micronised progesterone<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">f</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100-mg and 200-mg capsules&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#8722;200<span class="elsevierStyleHsp" style=""></span>mg oral&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Do not confuse progesterone with medroxyprogesterone&#46; This medicine contains peanut and&#47;or soybean oil and therefore should not be used in people with allergies to these foods&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Given the limited evidence of its effects on the growth of mammary alveoli&#44; its widespread use is not recommended in trans&#47;AMAB women&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">May increase risk of thrombosis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rectal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100<span class="elsevierStyleHsp" style=""></span>mg rectally at bedtime&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:6 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005"><span class="elsevierStyleItalic">Cyproterone acetate</span>&#58; contraindicated in severe depression&#44; liver disease&#44; thromboembolic disease or diabetes mellitus with microangiopathic involvement&#46; May increase the risk of meningiomas&#58; monitor cumulative dose&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010"><span class="elsevierStyleItalic">Spironolactone&#58;</span> although uncommon&#44; if the patient develops a skin rash or general malaise&#44; treatment should be suspended and the patient should be referred to the emergency department immediately &#40;drug rash with eosinophilia and systemic symptoms &#91;DRESS&#93; syndrome&#41;&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015"><span class="elsevierStyleItalic">Bicalutamide</span>&#58; contraindicated if there is a history of ischaemic heart disease or chronic heart failure&#46; Do not use in interstitial lung disease&#44; liver disease or prolonged QT interval &#40;as with flutamide&#41;&#46; Interaction with ritonavir&#47;indinavir and calcium channel blockers &#40;verapamil and diltiazem&#41;&#46; It should not be used as the first option&#44; given its potential adverse effects&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020"><span class="elsevierStyleItalic">Oestradiol valerate injection&#58;</span> commonly used in the US and Latin America&#44; as well as in Eastern Europe&#46; There are currently no formulations on the market in Spain&#46;</p>"
            ]
            4 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "e"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025"><span class="elsevierStyleItalic">Transdermal oestradiol</span>&#58; contact sensitisation occurs with all topical applications&#46; Although extremely rare&#44; women who develop contact sensitisation to any of the components of the patch should be warned that a serious hypersensitivity reaction could develop with continued exposure&#46;</p>"
            ]
            5 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "f"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030"><span class="elsevierStyleItalic">Progesterone</span>&#58; May be indicated in trans women &#40;&#60;50 years of age&#41; who do not achieve breast development beyond Tanner stage 3 despite receiving suitable doses of oestradiol and being on hormone therapy for more than 12&#8211;18 months&#46; If after six months there is no response&#44; it should be suspended&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Drugs used in feminising GAHT&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0045"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">IM&#58; intramuscular&#59; SC&#58; subcutaneous&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_colgroup " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Masculinising hormones<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">a</span></a></th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Testosterone cypionate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100-mg and 250-mg ampoule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100<span class="elsevierStyleHsp" style=""></span>mg every 14 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Short-acting preparations&#46; Does not mimic circadian rhythm&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">250<span class="elsevierStyleHsp" style=""></span>mg every 21 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SC<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#8722;100<span class="elsevierStyleHsp" style=""></span>mg SC weekly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">The same preparation is used intramuscularly &#40;off label&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Testosterone undecanoate&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-g ampoule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1<span class="elsevierStyleHsp" style=""></span>g&#47;3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">First dose of 1<span class="elsevierStyleHsp" style=""></span>g IM&#44; second dose at 6 weeks and then 1<span class="elsevierStyleHsp" style=""></span>g IM every 3 months&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Testosterone &#40;gel&#41;<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Transdermal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50-mg&#47;5-g sachet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 sachet per day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Risk of transfer to partner&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20<span class="elsevierStyleHsp" style=""></span>mg&#47;g &#40;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#8722;6 applications&#47;day &#40;40&#8722;60<span class="elsevierStyleHsp" style=""></span>mg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 application<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;5<span class="elsevierStyleHsp" style=""></span>g of gel<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>mg of testosterone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#46;2<span class="elsevierStyleHsp" style=""></span>mg&#47;g&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;3 applications&#47;day &#40;40&#46;5&#8722;60&#46;75<span class="elsevierStyleHsp" style=""></span>mg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 application<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1&#46;25<span class="elsevierStyleHsp" style=""></span>g of gel<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>20&#46;25<span class="elsevierStyleHsp" style=""></span>mg of testosterone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
            1 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Other preparations for use in trans men</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Active ingredient&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Presentation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Observations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Progestagens&#58; to stop menstruation or as contraceptives</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Norethisterone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5-mg and 10-mg tablets&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8722;10<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Statins increase its plasma concentration&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medroxyprogesterone<a class="elsevierStyleCrossRef" href="#tblfn0050"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5-mg and 10-mg tablets&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8722;10<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Administer in the first five days of the menstrual cycle&#46; Does not appear to increase the risk of thrombosis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Depo-Progevera &#91;Depo-Provera&#93; 150<span class="elsevierStyleHsp" style=""></span>mg&#47;ml ampoule&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Every three months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Does not appear to increase the risk of thrombosis&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Micronised progesterone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100-mg and 200-mg capsules&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">200&#8722;300<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">This medicine contains peanut and&#47;or soybean oil and therefore should not be used in people with allergies to these foods&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Etonogestrel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Intradermal implant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68-mg implant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Every three years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Menstruation may continue up to three months after placement&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Levonorgestrel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Intrauterine implant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Implant with an intrauterine release system of 0&#46;02<span class="elsevierStyleHsp" style=""></span>mg every 24<span class="elsevierStyleHsp" style=""></span>h&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Every five years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Can cause headache&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Aromatase inhibitors</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anastrozole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">May be beneficial in trans men with obesity and persistent menstruation&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Letrozole&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;5-mg tablet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Prior to testosterone therapy&#44; it is advisable to measure &#174;-HCG &#40;pregnancy test&#41; and screen for sleep apnoea&#47;hypopnoea syndrome &#40;SAHS&#41; with tools such as the STOP-BANG questionnaire&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">Subcutaneous use &#40;cypionate weekly&#41;&#58; same preparation as IM&#44; in which SC use is off-label&#46; Increasingly used&#44; as it yields more stable blood testosterone levels and possibly fewer side effects&#46; It could be considered the route of choice if not for the inconvenience of weekly administration and the fact that it has to be drawn using an insulin or 1-ml syringe&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0045">The use of testosterone gel in individuals under 18 years of age is off-label It should not be applied to the genital area &#40;penis&#44; testicles&#44; clitoris or vulva&#41; because its high alcohol content can cause local irritation&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Medroxyprogesterone&#46; Precautions&#58; it is necessary to take into account&#44; as well as investigate in a timely manner&#44; the history or appearance of the following conditions&#58; migraine or unusual severe headache&#44; acute visual alterations of any type&#44; pathological changes in liver function or hormone levels&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Hormonal preparations available for masculinising GAHT&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:29 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transgender medicine&#58; best practices and clinical care for the future"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "V&#46; Tangpricha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ecl.2019.03.001"
                      "Revista" => array:7 [
                        "tituloSerie" => "Endocrinol Metab Clin North Am"
                        "fecha" => "2019"
                        "volumen" => "48"
                        "numero" => "2"
                        "paginaInicial" => "xv"
                        "paginaFinal" => "xvii"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31655784"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "La perspectiva de despatologizaci&#243;n trans&#58; &#191;una aportaci&#243;n para enfoques de salud p&#250;blica y pr&#225;cticas cl&#237;nicas en salud mental&#63; Informe SESPAS 2020"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "A&#46;S&#46; Schwend"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gaceta.2020.07.002"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gac Sanit"
                        "fecha" => "2020"
                        "volumen" => "34"
                        "numero" => "Suppl 1"
                        "paginaInicial" => "54"
                        "paginaFinal" => "60"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32919815"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gender development and clinical presentation of gender nonconformity in children and adolescents&#46; UpToDate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46;D&#46; Forcier"
                            1 => "M&#46;D&#46; Johanna Olson-Kennedy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;www&#46;uptodate&#46;com&#47;contents&#47;gender-development-and-clinical-presentation-of-gender-diversity-in-children-and-adolescents"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gender is a multifaceted concept&#58; evidence that specific life experiences differentially shape the concept of gender"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46; Mazzuca"
                            1 => "A&#46; Majid"
                            2 => "L&#46; Lugli"
                            3 => "R&#46; Nicoletti"
                            4 => "A&#46;M&#46; Borghi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.31219/osf.io/ugv43"
                      "Revista" => array:4 [
                        "tituloSerie" => "Lang Cogn"
                        "fecha" => "2020"
                        "paginaInicial" => "1"
                        "paginaFinal" => "30"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Manual Diagn&#243;stico y Estad&#237;stico De Los Trastornos Mentales &#40;DSM-5&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "American Psychiatric Association &#40;APA&#41;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:4 [
                        "edicion" => "5the ed&#46;"
                        "fecha" => "2014"
                        "editorial" => "Editorial M&#233;dica Panamericana"
                        "editorialLocalizacion" => "Madrid"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transgender community belongingness as a mediator between strength of transgender identity and well-being"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Barr"
                            1 => "S&#46;L&#46; Budge"
                            2 => "J&#46;L&#46; Adelson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1037/cou0000127"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Couns Psychol"
                        "fecha" => "2016"
                        "volumen" => "63"
                        "numero" => "1"
                        "paginaInicial" => "87"
                        "paginaFinal" => "97"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26751157"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Percepci&#243;n de la Salud y Relaci&#243;n con el Personal Sanitario&#46; En&#58; Informe &#8220;Las personas Trans y su relaci&#243;n con el sistema sanitario&#8221;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Federaci&#243;n Espa&#241;ola de lesbianas&#44; gais&#44; trans y bisexuales &#40;FELGTB&#41;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "fecha" => "2020"
                        "editorial" => "Ministerio de Sanidad&#44; Consumo y Bienestar Social"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global health burden and needs of transgender populations&#58; a review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;L&#46; Reisner"
                            1 => "T&#46; Poteat"
                            2 => "J&#46; Keatley"
                            3 => "M&#46; Cabral"
                            4 => "T&#46; Mothopeng"
                            5 => "E&#46; Dunham"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(16)00684-X"
                      "Revista" => array:7 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2016"
                        "volumen" => "388"
                        "numero" => "10042"
                        "paginaInicial" => "412"
                        "paginaFinal" => "436"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27323919"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Endocrine treatment of gender-dysphoric&#47;gender-incongruent persons&#58; an endocrine society clinical practice guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "W&#46;C&#46; Hembree"
                            1 => "P&#46;T&#46; Cohen-Kettenis"
                            2 => "L&#46; Gooren"
                            3 => "S&#46;E&#46; Hannema"
                            4 => "W&#46;J&#46; Meyer"
                            5 => "M&#46;H&#46; Murad"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4158/1934-2403-23.12.1437"
                      "Revista" => array:6 [
                        "tituloSerie" => "Endocr Pract"
                        "fecha" => "2017"
                        "volumen" => "23"
                        "numero" => "12"
                        "paginaInicial" => "1437"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29320642"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Standards of care for the health of transsexual&#44; transgender&#44; and gender-nonconforming people"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "World Professional Association for Transgender Health"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "Libro" => array:4 [
                        "edicion" => "7th ed&#46;"
                        "fecha" => "2012"
                        "editorial" => "World Professional Association for Transgender Health"
                        "editorialLocalizacion" => "Minneapolis"
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;www&#46;wpath&#46;org&#47;publications&#47;soc"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guidelines for psychological practice with transgender and gender nonconforming people"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "American Psychological Association"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1037/a0039906"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Psychol"
                        "fecha" => "2015"
                        "volumen" => "70"
                        "paginaInicial" => "832"
                        "paginaFinal" => "864"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26653312"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lesbian&#44; gay&#44; bisexual and transgender health&#58; obstetrician-gynecologists&#8217; training&#44; attitudes&#44; knowledge&#44; and practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46;K&#46; Mehta"
                            1 => "S&#46;R&#46; Easter"
                            2 => "J&#46; Potter"
                            3 => "N&#46; Castleberry"
                            4 => "J&#46; Schulkin"
                            5 => "J&#46;N&#46; Robinson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1089/jwh.2017.6912"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Women&#8217;s Health"
                        "fecha" => "2018"
                        "volumen" => "27"
                        "numero" => "12"
                        "paginaInicial" => "1459"
                        "paginaFinal" => "1495"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Barriers to gender-affirming care for transgender and gender nonconforming individuals"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;A&#46; Puckett"
                            1 => "P&#46; Cleary"
                            2 => "K&#46; Rossman"
                            3 => "B&#46; Mustanski"
                            4 => "M&#46;E&#46; Newcomb"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13178-017-0295-8"
                      "Revista" => array:7 [
                        "tituloSerie" => "Sex Res Social Policy"
                        "fecha" => "2017"
                        "volumen" => "15"
                        "numero" => "1"
                        "paginaInicial" => "48"
                        "paginaFinal" => "59"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29527241"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transgender and gender nonconforming in emergency departments&#58; a qualitative report of patient experiences"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Chisolm-Straker"
                            1 => "L&#46; Jardine"
                            2 => "C&#46; Bennouna"
                            3 => "N&#46; Morency-Brassard"
                            4 => "L&#46; Coy"
                            5 => "M&#46;O&#46; Egemba"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1089/trgh.2016.0026"
                      "Revista" => array:7 [
                        "tituloSerie" => "Transgend Health"
                        "fecha" => "2017"
                        "volumen" => "2"
                        "numero" => "1"
                        "paginaInicial" => "8"
                        "paginaFinal" => "16"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28861544"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "CIE-11 and the depathologisation of the transgender condition"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Robles Garc&#237;a"
                            1 => "J&#46;L&#46; Ayuso-Mateos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rpsm.2019.01.002"
                      "Revista" => array:7 [
                        "tituloSerie" => "Rev Psiquiatr Salud Ment &#40;Engl Ed&#41;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "numero" => "2"
                        "paginaInicial" => "65"
                        "paginaFinal" => "67"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30846280"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Endocrinology of transgender medicine"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "G&#46; T&#8217;Sjoen"
                            1 => "J&#46; Arcelus"
                            2 => "L&#46; Gooren"
                            3 => "D&#46;T&#46; Klink"
                            4 => "V&#46; Tangpricha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/er.2018-00011"
                      "Revista" => array:8 [
                        "tituloSerie" => "Endocr Rev"
                        "fecha" => "2019"
                        "volumen" => "40"
                        "numero" => "1"
                        "paginaInicial" => "97"
                        "paginaFinal" => "117"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30307546"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1935861X16000024"
                          "estado" => "S300"
                          "issn" => "1935861X"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ley Org&#225;nica 10&#47;1995&#44; de 23 de noviembre&#44; del C&#243;digo Penal&#46; &#91;Accessed 10 December 2021&#93;&#46; Available from&#58; <a target="_blank" href="https://www.boe.es/buscar/act.php?id=BOE-A-1995-25444">https&#58;&#47;&#47;www&#46;boe&#46;es&#47;buscar&#47;act&#46;php&#63;id&#61;BOE-A-1995-25444</a>&#46;"
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Toward a lowest effective dose of cyproterone acetate in trans women&#58; results from the ENIGI study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46;M&#46;E&#46; Kuijpers"
                            1 => "C&#46;M&#46; Wiepjes"
                            2 => "E&#46;B&#46; Conemans"
                            3 => "A&#46;D&#46; Fisher"
                            4 => "G&#46; T&#8217;Sjoen"
                            5 => "M&#46; den Heijer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/clinem/dgab427"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Clin Endocrinol Metab"
                        "fecha" => "2021"
                        "volumen" => "106"
                        "numero" => "10"
                        "paginaInicial" => "e3936"
                        "paginaFinal" => "e3945"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34125226"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacology of estrogens and progestogens&#58; influence of different routes of administration"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "H&#46; Kuhl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13697130500148875"
                      "Revista" => array:6 [
                        "tituloSerie" => "Climacteric"
                        "fecha" => "2005"
                        "volumen" => "8"
                        "paginaInicial" => "3"
                        "paginaFinal" => "63"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16112947"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of high dose cyproterone acetate and risk of intracranial meningioma in women&#58; cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Weill"
                            1 => "P&#46; Nguyen"
                            2 => "M&#46; Labidi"
                            3 => "B&#46; Cadier"
                            4 => "T&#46; Passeri"
                            5 => "L&#46; Duranteau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/bmj.n37"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMJ"
                        "fecha" => "2021"
                        "volumen" => "372"
                        "paginaInicial" => "n37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33536184"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The Report of the 2015 U&#46;S&#46; Transgender Survey"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46;E&#46; Burnier James"
                            1 => "J&#46;L&#46; Herman"
                            2 => "S&#46; Rankin"
                            3 => "M&#46; Keisling"
                            4 => "L&#46; Mottet"
                            5 => "M&#46; Anafi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2016"
                        "editorial" => "National Center for Transgender Equality"
                        "editorialLocalizacion" => "Washington&#44; DC"
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;transequality&#46;org&#47;sites&#47;default&#47;files&#47;docs&#47;usts&#47;USTS-Full-Report-Dec17&#46;pdf"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of endocrine disease&#58; optimal feminizing hormone treatment in transgender people"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Glintborg"
                            1 => "G&#46; T&#8217;Sjoen"
                            2 => "P&#46; Ravn"
                            3 => "M&#46;S&#46; Andersen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1530/EJE-21-0059"
                      "Revista" => array:7 [
                        "tituloSerie" => "Eur J Endocrinol"
                        "fecha" => "2021"
                        "volumen" => "185"
                        "numero" => "2"
                        "paginaInicial" => "R49"
                        "paginaFinal" => "R63"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34081614"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An approach to nonsuppressed testosterone in transgender women receiving gender-affirming feminizing hormonal therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Maheshwari"
                            1 => "T&#46; Nippoldt"
                            2 => "C&#46; Davidge-Pitts"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1210/jendso/bvab068"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Endocr Soc"
                        "fecha" => "2021"
                        "volumen" => "5"
                        "numero" => "9"
                        "paginaInicial" => "bvab068"
                        "itemHostRev" => array:3 [
                          "pii" => "S1474442218300322"
                          "estado" => "S300"
                          "issn" => "14744422"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cap&#237;tulo 12&#46; La sexualidad en la juventud"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Sim&#243;n"
                            1 => "C&#46; Claver&#237;a"
                            2 => "G&#46; Garc&#237;aAlbacete"
                            3 => "A&#46; L&#243;pez Ortega"
                            4 => "M&#46; Torre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "Libro" => array:5 [
                        "titulo" => "Informe&#46; Juventud en Espa&#241;a 2020"
                        "fecha" => "2021"
                        "paginaInicial" => "322"
                        "paginaFinal" => "323"
                        "editorial" => "Instituto de la Juventud &#40;INJUVE&#41;"
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;www&#46;injuve&#46;es&#47;sites&#47;default&#47;files&#47;adjuntos&#47;2021&#47;03&#47;informe&#95;juventud&#95;espana&#95;2020&#46;pdf"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hormonal treatment strategies tailored to non-binary transgender individuals"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46; Cocchetti"
                            1 => "J&#46; Ristori"
                            2 => "A&#46; Romani"
                            3 => "M&#46; Maggi"
                            4 => "A&#46;D&#46; Fisher"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/jcm9061609"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Med"
                        "fecha" => "2020"
                        "volumen" => "9"
                        "numero" => "6"
                        "paginaInicial" => "1609"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32466485"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oestrogen and anti-androgen therapy for transgender women"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Tangpricha"
                            1 => "M&#46; den Heijer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-8587(16)30319-9"
                      "Revista" => array:7 [
                        "tituloSerie" => "Lancet Diabetes Endocrinol"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "numero" => "4"
                        "paginaInicial" => "291"
                        "paginaFinal" => "300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27916515"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Testosterone therapy for transgender men"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "M&#46;S&#46; Irwig"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2213-8587(16)00036-X"
                      "Revista" => array:7 [
                        "tituloSerie" => "Lancet Diabetes Endocrinol"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "numero" => "4"
                        "paginaInicial" => "301"
                        "paginaFinal" => "311"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27084565"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transexualidad&#58; transiciones&#44; detransiciones y arrepentimientos en Espa&#241;a"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Pazos Guerra"
                            1 => "M&#46; G&#243;mez Balaguer"
                            2 => "M&#46; Gomes Porras"
                            3 => "F&#46; Hurtado Murillo"
                            4 => "E&#46; Sol&#225; Izquierdo"
                            5 => "C&#46; Morillas Ari&#241;o"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.endinu.2020.03.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "Endocrinol Diabetes Nutr"
                        "fecha" => "2020"
                        "volumen" => "67"
                        "numero" => "9"
                        "paginaInicial" => "562"
                        "paginaFinal" => "567"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gu&#237;as de pr&#225;ctica cl&#237;nica para la valoraci&#243;n y tratamiento de la transexualidad&#46; Grupo de Identidad y Diferenciaci&#243;n Sexual de la SEEN &#40;GIDSEEN"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "O&#46; Moreno-P&#233;rez"
                            1 => "I&#46; Esteva De Antonio"
                            2 => "Grupo de Identidad y Diferenciaci&#243;n Sexual de la SEEN &#40;GIDSEEN&#41;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.endonu.2012.02.001"
                      "Revista" => array:7 [
                        "tituloSerie" => "Endocrinol Nutr"
                        "fecha" => "2012"
                        "volumen" => "59"
                        "numero" => "6"
                        "paginaInicial" => "367"
                        "paginaFinal" => "382"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22542505"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/25300180/00000070000000S1/v2_202304211110/S2530018022001652/v2_202304211110/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/25300180/00000070000000S1/v2_202304211110/S2530018022001652/v2_202304211110/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530018022001652?idApp=UINPBA00004N"
]

Article information

ISSN: 25300180
Original language: English

DOI:10.1016/j.endien.2022.11.007

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	15	0	15
2024 October	56	8	64
2024 September	75	7	82
2024 August	78	18	96
2024 July	99	10	109
2024 June	92	12	104
2024 May	71	4	75
2024 April	138	13	151
2024 March	91	14	105
2024 February	88	5	93
2024 January	81	18	99
2023 December	61	10	71
2023 November	71	7	78
2023 October	42	3	45
2023 September	33	2	35

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter